EP3728223A1 - Azines triazoles d'acide cyclohexyle utilisées en tant qu'antagonistes de lpa - Google Patents

Azines triazoles d'acide cyclohexyle utilisées en tant qu'antagonistes de lpa

Info

Publication number
EP3728223A1
EP3728223A1 EP18830681.5A EP18830681A EP3728223A1 EP 3728223 A1 EP3728223 A1 EP 3728223A1 EP 18830681 A EP18830681 A EP 18830681A EP 3728223 A1 EP3728223 A1 EP 3728223A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
lpa
fibrosis
mmol
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP18830681.5A
Other languages
German (de)
English (en)
Other versions
EP3728223B1 (fr
Inventor
Yan Shi
Ying Wang
Peter Tai Wah Cheng
Jun Shi
Shiwei Tao
James R. Corte
Tianan Fang
Jun Li
Lawrence J. Kennedy
III Robert F. Kaltenbach
Sutjano JUSUF
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EP3728223A1 publication Critical patent/EP3728223A1/fr
Application granted granted Critical
Publication of EP3728223B1 publication Critical patent/EP3728223B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Definitions

  • the present invention relates to novel substituted triazole compounds
  • compositions containing them, and methods of using them for example, for the treatment of disorders associated with one or more of the lysophosphatidic acid (LPA) receptors.
  • LPA lysophosphatidic acid
  • Lysophospholipids are membrane-derived bioactive lipid mediators, of which one of the most medically important is lysophosphatidic acid (LPA).
  • LPA lysophosphatidic acid
  • LPA is not a single molecular entity but a collection of endogenous structural variants with fatty acids of varied lengths and degrees of saturation (Fujiwara et al., J Biol. Chem ., 2005, 280 , 35038- 35050).
  • the structural backbone of the LPAs is derived from glycerol -based
  • phospholipids such as phosphatidylcholine (PC) or phosphatidic acid (PA).
  • PC phosphatidylcholine
  • PA phosphatidic acid
  • the LPAs are bioactive lipids (signaling lipids) that regulate various cellular signaling pathways by binding to the same class of 7-transmembrane domain G protein- coupled (GPCR) receptors (Chun, J., Hla, T., Spiegel, S., Moolenaar, W., Editors, Lysophospholipid Receptors: Signaling and Biochemistry, 2013, Wiley; ISBN: 978-0- 470-56905-4 & Zhao, Y. et al, Biochim. Biophys. Acta (BBA)-Mol. Cell Biol. Of Lipids, 2013, 1831, 86-92).
  • GPCR G protein- coupled
  • LPAi LPA 2 , LPA 3 , LPA 4 , LPA S and LPA 6
  • LPAi LPA 2 , LPA 3 , LPA 4 , LPA S and LPA 6
  • the LPAs have long been known as precursors of phospholipid biosynthesis in both eukaryotic and prokaryotic cells, but the LPAs have emerged only recently as signaling molecules that are rapidly produced and released by activated cells, notably platelets, to influence target cells by acting on specific cell-surface receptors (see, e.g, Moolenaar et al., BioEssays, 2004, 26, 870-881, and van Leewen et al., Biochem. Soc. Trans., 2003, 37, 1209-1212).
  • LPAs can be generated through the hydrolysis of pre-existing phospholipids following cell activation; for example, the sn-2 position is commonly missing a fatty acid residue due to deacylation, leaving only the sn- 1 hydroxyl esterified to a fatty acid.
  • autotaxin lysoPLD/NPP2
  • lysoPLD/NPP2 may be the product of an oncogene, as many tumor types up- regulate autotaxin (Brindley, D., J. Cell Biochem. 2004, 92, 900-12).
  • LPA influences a wide range of biological responses, ranging from induction of cell proliferation, stimulation of cell migration and neurite retraction, gap junction closure, and even slime mold chemotaxis (Goetzl, et al., Scientific World J., 2002, 2, 324- 338; Chun, J., Hla, T., Spiegel, S., Moolenaar, W., Editors, Lysophospholipid Receptors: Signaling and Biochemistry, 2013, Wiley; ISBN: 978-0-470-56905-4).
  • the body of knowledge about the biology of LPA continues to grow as more and more cellular systems are tested for LPA responsiveness.
  • LPAs promote cellular tension and cell- surface fibronectin binding, which are important events in wound repair and regeneration (Moolenaar et al., BioEssays, 2004, 26, 870-881). Recently, anti-apoptotic activity has also been ascribed to LPA, and it has recently been reported that PPARy is a
  • Fibrosis is the result of an uncontrolled tissue healing process leading to excessive accumulation and insufficient resorption of extracellular matrix (ECM) which ultimately results in end-organ failure (Rockey, D. C., et al., New Engl. J. Med., 2015, 372, 1138- 1149).
  • ECM extracellular matrix
  • the LPAi receptor has been reported to be over-expressed in idiopathic pulmonary fibrosis (IPF) patients. LPAi receptor knockout mice were protected from bleomycin- induced lung fibrosis (Tager et al., Nature Med., 2008, 14, 45-54).
  • LPAi antagonist BMS-986020 was shown to significantly reduce the rate of FVC (forced vital capacity) decline in a 26-week clinical trial in IPF patients (Palmer et al., Chest, 2018, 154, 1061- 1069).
  • LPA pathway inhibitors e.g. an LPAi antagonist
  • antagonizing the LPAi receptor may be useful for the treatment of fibrosis such as pulmonary fibrosis, hepatic fibrosis, renal fibrosis, arterial fibrosis and systemic sclerosis, and thus the diseases that result from fibrosis (pulmonary fibrosis-idiopathic Pulmonary Fibrosis [IPF], hepatic fibrosis-Non-alcoholic Steatohepatitis [NASH], renal fibrosis-diabetic nephropathy, systemic sclerosis-scleroderma, etc.)
  • fibrosis such as pulmonary fibrosis, hepatic fibrosis, renal fibrosis, arterial fibrosis and systemic sclerosis
  • diseases that result from fibrosis pulmonary fibrosis-idiopathic Pulmonary Fibrosis [IPF]
  • hepatic fibrosis-Non-alcoholic Steatohepatitis [NASH] hepatic fibrosis-N
  • the present invention provides novel substituted triazole compounds including stereoisomers, tautomers, and pharmaceutically acceptable salts or solvates thereof, which are useful as antagonists against one or more of the lysophosphatidic acid (LPA) receptors, especially the LPAi receptor.
  • LPA lysophosphatidic acid
  • the present invention also provides processes and intermediates for making the compounds of the present invention.
  • the present invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier and at least one of the compounds of the present invention or stereoisomers, tautomers, pharmaceutically acceptable salts or solvates thereof.
  • the compounds of the invention may be used in the treatment of conditions in which LPA plays a role.
  • the compounds of the present invention may be used in therapy.
  • the compounds of the present invention may be used for the manufacture of a medicament for the treatment of a condition in which inhibition of the physiological activity of LPA is useful, such as diseases in which an LPA receptor participates, is involved in the etiology or pathology of the disease, or is otherwise associated with at least one symptom of the disease.
  • the present invention is directed to a method of treating fibrosis of organs (liver, kidney, lung, heart and the like as well as skin), liver diseases (acute hepatitis, chronic hepatitis, liver fibrosis, liver cirrhosis, portal hypertension, regenerative failure, non-alcoholic steatohepatitis (NASH), liver hypofunction, hepatic blood flow disorder, and the like), cell proliferative disease [cancer (solid tumor, solid tumor metastasis, vascular fibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leukemia, chronic lymphocytic leukemia (CLL) and the like) and invasive metastasis of cancer cell, and the like], inflammatory disease (psoriasis, nephropathy, pneumonia and the like), gastrointestinal tract disease (irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), abnormal pancreatic secretion, and the like),
  • the present invention is directed to a method of treating diseases, disorders, or conditions in which activation of at least one LPA receptor by LPA contributes to the symptomology or progression of the disease, disorder or condition.
  • diseases, disorders, or conditions may arise from one or more of a genetic, iatrogenic, immunological, infectious, metabolic, oncological, toxic, surgical, and/or traumatic etiology.
  • the present invention is directed to a method of treating renal fibrosis, pulmonary fibrosis, hepatic fibrosis, arterial fibrosis and systemic sclerosis comprising administering to a patient in need of such treatment a compound of the present invention as described above.
  • the present invention provides methods, compounds,
  • compositions, and medicaments described herein that comprise antagonists of LPA receptors, especially antagonists of LPAi.
  • the compounds of the invention can be used alone, in combination with other compounds of the present invention, or in combination with one or more, preferably one to two other agent(s).
  • the present invention provides, inter alia , compounds of Formula
  • X 1 , X 2 , X 3 , and X 4 are each independently CR 5 or N; provided that no more than two of X 1 , X 2 , X 3 , or X 4 are N;
  • one of Q 1 , Q 2 , and Q 3 is NR 6 , and the other two are N; and the dashed circle denotes optional bonds forming an aromatic ring;
  • L is a covalent bond or Ci -4 alkyl ene substituted with 0 to 4 R 7 ;
  • Z is CHR 8a , NR 8b or O;
  • the Y ring is phenyl or an azine moiety; wherein the term“azine” refers to 6- membered heteroaryl wherein the ring members are selected from CH and 1 to 4 nitrogen; and in one embodiment, the azine moiety is a ring moiety selected from pyridine, diazine (e.g., pyrimidine, pyrazine, and pyridazine), triazine, and tetrazine;
  • R 1 is (-CH 2 ) a R 9 ;
  • R 2 is each independently halo, cyano, hydroxyl, amino, Ci- 6 alkyl, C3-6 cycloalkyl, 4- to 6-membered heterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, alkoxyalkyl, haloalkoxyalkyl, or haloalkoxy;
  • n is an integer of 0, 1, or 2;
  • R a is selected from Ci -6 alkyl, Ci- 6 deuterated alkyl (fully or partially deuterated), haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, carbocyclyl, carbocyclylalkyl, heterocyclyl, and
  • R b is each independently hydrogen or R a ;
  • R c is each independently R b ; or alternatively, two R c , taken together with the nitrogen atom to which they are attached, form a 4- to 7-membered heterocyclyl;
  • R 4 is each independently halo, cyano, hydroxyl, amino, Ci- 6 alkyl, C3-6 cycloalkyl, 4- to 6-membered heterocyclyl, 5 or 6-membered heteroaryl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, alkoxyalkyl, haloalkoxyalkyl, or haloalkoxy; or R 3 and R 4 , taken together with the atoms to which they are attached, form a monocyclic or bicyclic ring moiety;
  • n is an integer of 0, 1, or 2;
  • R 5 is hydrogen, halo, cyano, hydroxyl, amino, Ci- 6 alkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy;
  • R 6 is hydrogen, Ci- 6 alkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy;
  • R 7 is halo, oxo, cyano, hydroxyl, amino, Ci- 6 alkyl, C3-6 cycloalkyl, 4- to 6- membered heterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy;
  • R 8a is hydrogen, halo, hydroxyl, cyano, or C 1-4 alkyl
  • R 8b is hydrogen or C 1-4 alkyl
  • R 9 is selected from -CN, -C(0)OR 10 , -C(0)NR lla R llb ,
  • R e is Ci-6 alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, or
  • R 10 is hydrogen or C 1-10 alkyl; and R lla and R llb are each independently hydrogen, Ci- 6 alkyl, C3-6 cycloalkyl, 4- to 6- membered heterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy.
  • R 3 is halo, cyano, hydroxyl, amino,
  • Ci- 6 alkyl Ci- 6 deuterated alkyl (fully or partially deuterated), Ci- 6 heteroalkyl, 6- to lO-membered aryl, arylalkyl, 5- to lO-membered heteroaryl, heteroarylalkyl, 3- to 8-membered carbocyclyl, carbocyclylalkyl, 4- to 8-membered heterocyclyl, or heterocyclylalkyl; wherein the alkyl, heteroalkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, and R a , by themselves or as part of another group, are each independently substituted with 0 to 5 R d .
  • X 2 is CR 5 , where R 5 is hydrogen or C1-4 alkyl
  • R 6 is hydrogen or Ci- 6 alkyl.
  • L is a covalent bond or methylene.
  • Y 1 , Y 2 , Y 3 , and Y 4 are each independently N or CH with the proviso that at least one of Y 1 , Y 2 , Y 3 , and Y 4 is CH. In one embodiment, two of Y 1 , Y 2 , Y 3 , and Y 4 are CH. In another embodiment, three of Y 1 , Y 2 , Y 3 , and Y 4 are CH. In another embodiment, Y 1 , Y 2 , Y 3 , and Y 4 are all CH.
  • R 3 is halo, cyano, hydroxyl, amino, -OR a , -SR a , -NR C R C , Ci- 6 alkyl, Ci- 6 deuterated alkyl, Ci- 6 heteroalkyl, 6- to lO-membered aryl, arylalkyl, 5- to lO-membered heteroaryl, heteroarylalkyl, 3- to 8-membered carbocyclyl, carbocyclylalkyl, 4- to 8-membered heterocyclyl, or heterocyclylalkyl; wherein the alkyl, heteroalkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, and R a , by themselves or as part of another group, are each independently substituted with 0 to 5 R d ,
  • R a is selected from Ci -6 alkyl, Ci- 6 deuterated alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, carbocyclyl, carbocyclylalkyl, heterocyclyl, and heterocyclylalkyl;
  • R b is each independently hydrogen or R a ;
  • R c is each independently R b ; or alternatively, two R c , taken together with the nitrogen atom to which they are attached, form a 4- to 7-membered heterocyclyl;
  • R d is each independently selected from R a , alkoxy, haloalkoxy, alkylamino, cycloalkylamino, heterocyclylamino, haloalkyl, hydroxyalkyl, aminoalkyl, cycloalkoxy, heterocyclyloxy, haloalkoxy, alkoxyalkoxy, haloalkylamino, alkoxyalkylamino, haloalkoxyalkylamino, arylamino, aralkylamino, aryloxy, aralkyloxy, heteroaryl oxy, heteroarylalkyloxy, alkylthio, halo, cyano, hydroxyl, amino, oxo, -OR a , -SR a , and -NR C R C ; or alternatively one or two R d on alkyl, heteroalkyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl, taken together with the atom
  • the compound is represented by Formula (Ha), (lib), (lie), or (lid):
  • U 1 , U 2 , U 3 , and U 4 are each independently N or CH;
  • R 7a is hydrogen, halo, oxo, cyano, hydroxyl, amino, Ci- 6 alkyl, C3-6 cycloalkyl, 4- to 6-membered heterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy;
  • f is an integer of 0, 1, or 2;
  • n 0 or 1
  • R 1 , R 2 , n, R 3 , R 4 , R 6 , m, X 1 , X 2 , X 3 , X 4 , and Z are the same as defined above.
  • X 1 is CR 5 , where R 5 is hydrogen or C 1-4 alkyl.
  • R 5a is each independently halo, cyano, hydroxyl, amino, Ci- 6 alkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy;
  • d is an integer of 0, 1, or 2.
  • f is 0 or 1.
  • R 7a is hydrogen.
  • R 8a or R 8b is hydrogen.
  • R 1 is CO2FL In one embodiment, R 2 is hydrogen.
  • the compound is represented by Formula (Ilia), (Illb), or (IIIc):
  • Y 1 , Y 2 , and U 3 are each independently N or CH;
  • L is a covalent bond or CH 2 ;
  • Z is CH 2 , O or NH; provided that L and Z are not both CH 2 ;
  • R 2a is hydrogen, chloro, fluoro, or Ci- 4 alkyl
  • R 6 is hydrogen or Ci- 6 alkyl
  • R 1 , R 3 , R 4 , R 6 , m, X 1 , X 2 , X 3 , and X 4 are the same as defined above.
  • one of Y 1 , Y 2 , and Y 3 is CH. In another embodiment, two of Y 1 , Y 2 , and Y 3 are CH. In another embodiment, Y 1 , Y 2 , and Y 3 are all CH.
  • R 1 is
  • X 1 is CR 5 ;
  • X 2 is N or CH;
  • X 3 is N; and
  • X 4 is N or CH; and
  • R 5 is hydrogen, halo, cyano, Ci- 6 alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, or alkoxy.
  • X 4 is CH.
  • R 5 is hydrogen, methyl, or ethyl.
  • m 0 or 1.
  • m 0 or 1.
  • R 3 is halo, cyano, hydroxyl, amino, -OR a , -SR a , -NR C R C , Ci- 6 alkyl, Ci- 6 haloalkyl, Ci- 6 heteroalkyl, 6- to lO-membered aryl, arylalkyl, 5- to lO-membered heteroaryl, heteroarylalkyl, 3- to 8-membered carbocyclyl, carbocyclylalkyl, 4- to 8-membered heterocyclyl, or heterocyclylalkyl; wherein the alkyl, heteroalkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, and R a , by themselves or as part of another group, are each independently substituted with 0 to 5 R d ; wherein the alkyl includes a fully or partially deuterated alkyl;
  • R a is selected from Ci -6 alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, carbocyclyl,
  • R b is each independently hydrogen or R a ;
  • R c is each independently R b ; or alternatively, two R c , taken together with the nitrogen atom to which they are attached, form a 4- to 7-membered heterocyclyl;
  • R d is each independently selected from R a , alkoxy, haloalkoxy, alkylamino, cycloalkylamino, heterocyclylamino, haloalkyl, hydroxyalkyl, aminoalkyl, cycloalkoxy, heterocyclyloxy, haloalkoxy, alkoxyalkoxy, haloalkylamino, alkoxyalkylamino, haloalkoxyalkylamino, arylamino, aralkylamino, aryloxy, aralkyloxy, heteroaryl oxy, heteroarylalkyloxy, alkylthio, halo, cyano, hydroxyl, amino, oxo, -OR a , -SR a ,
  • R d on alkyl, heteroalkyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl, taken together with the atoms to which the R d is attached, form a cyclic or bridge moiety.
  • n 0, 1, or 2;
  • R 4 is each independently halo, cyano, hydroxyl, amino, Ci- 6 alkyl, C3-6 cycloalkyl, 4- to 6-membered heterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, alkoxyalkyl, haloalkoxyalkyl, or haloalkoxy.
  • R 3 is C1-6 alkyl, Ci- 6 haloalkyl, Ci- 6 alkoxy, deuterated Ci- 6 alkoxy, Ci- 6 haloalkoxy,
  • C3-6 cycloalkyl 4- to 6-membered heterocyclyl, phenyl, (a 5 or 6-membered heteroaryl containing 1 to 3 heteroatoms each of which is independently selected from N, O, and S), -(C1-3 alkylene)-(C3-6 cycloalkyl), -(C1-3 alkylene)-(phenyl), -0-(C3-6 cycloalkyl),
  • -NH-haloalkyl -NH-phenyl, -NH-cycloalkyl, and -N(alkyl) 2 ; and the alkyl, alkylene, cycloalkyl, phenyl, heterocyclyl, and heteroaryl, by themselves or as part of another group, are each independently substituted with 0 to 3 R d ; and R d is halo, cyano, hydroxyl, amino, Ci- 6 alkyl, Ci- 6 alkoxy, C3-6 cycloalkyl, or 4- to 6-membered heterocyclyl.
  • R 3 is Ci-6 alkyl, Ci- 6 haloalkyl, Ci- 6 alkoxy, deuterated Ci- 6 alkoxy, Ci- 6 haloalkoxy, C3-6 cycloalkyl, 4- to 6-membered heterocyclyl, phenyl, (a 5 or 6-membered heteroaryl containing 1 to 3 heteroatoms each of which is independently selected from N, O, and S), -(C1-3 alkylene)-(C3-6 cycloalkyl), -(C1-3 alkylene)-(phenyl), -0-(C3-6 cycloalkyl),
  • the compound is selected from any one of the Examples as described in the specification, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof.
  • the compound is selected from Examples 1 to 408 as described in the specification, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof.
  • the compound is selected from Examples 1 to 248 as described in the specification, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof.
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compound is selected from:
  • the compounds of the present invention have hLPAi IC50 values ⁇ 5000 nM, using the LPAi functional antagonist assay; in another embodiment, the compounds of the present invention have hLPAi IC50 values ⁇ 1000 nM; in another embodiment, the compounds of the present invention have hLPAi IC50 values ⁇ 500 nM; in another embodiment, the compounds of the present invention have hLPAi IC50 values ⁇ 200 nM; in another embodiment, the compounds of the present invention have hLPAi IC50 values ⁇ 100 nM; in another embodiment, the compounds of the present invention have hLPAi IC50 values ⁇ 50 nM.
  • the compound of Formulas (I), or a pharmaceutically acceptable salt or solvate thereof is an antagonist of at least one LPA receptor. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, is an antagonist of LPAi. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, is an antagonist of LPA 2. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, is an antagonist of LPA 3.
  • presented herein are compounds selected from active metabolites, tautomers, pharmaceutically acceptable salts or solvates of a compound of Formula (I).
  • the present invention provides a composition comprising at least one of the compounds of the present invention or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof.
  • the present invention provides a pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof.
  • the present invention provides a process for making a compound of the present invention.
  • the present invention provides an intermediate for making a compound of the present invention.
  • the present invention provides a pharmaceutical composition further comprising additional therapeutic agent(s).
  • the present invention provides a method for the treatment of a condition associated with LPA receptor mediated fibrosis, comprising administering to a patient in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof.
  • the term "patient” encompasses all mammalian species.
  • the present invention provides a method of treating a disease, disorder, or condition associated with dysregulation of lysophosphatidic acid receptor 1 (LPAi) in a patient in need thereof, comprising administering a therapeutically effective amount of a compound of the present invention, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, to the patient.
  • LPAi lysophosphatidic acid receptor 1
  • the disease, disorder, or condition is related to pathological fibrosis, transplant rejection, cancer, osteoporosis, or inflammatory disorders.
  • the pathological fibrosis is pulmonary, liver, renal, cardiac, demal, ocular, or pancreatic fibrosis.
  • the disease, disorder, or condition is idiopathic pulmonary fibrosis (IPF), non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, and systemic sclerosis.
  • the cancer is of the bladder, blood, bone, brain, breast, central nervous system, cervix, colon, endometrium, esophagus, gall bladder, genitalia, genitourinary tract, head, kidney, larynx, liver, lung, muscle tissue, neck, oral or nasal mucosa, ovary, pancreas, prostate, skin, spleen, small intestine, large intestine, stomach, testicle, or thyroid.
  • the present invention provides a method of treating fibrosis in a mammal comprising administering a therapeutically effective amount of a compound of the present invention, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, to the mammal in need thereof.
  • the fibrosis is idiopathic pulmonary fibrosis (IPF), nonalcoholic
  • NASH steatohepatitis
  • chronic kidney disease diabetic kidney disease
  • systemic sclerosis systemic sclerosis
  • the present invention provides a method of treating lung fibrosis (idiopathic pulmonary fibrosis), asthma, chronic obstructive pulmonary disease (COPD), renal fibrosis, acute kidney injury, chronic kidney disease, liver fibrosis (non alcoholic steatohepatitis), skin fibrosis, fibrosis of the gut, breast cancer, pancreatic cancer, ovarian cancer, prostate cancer, glioblastoma, bone cancer, colon cancer, bowel cancer, head and neck cancer, melanoma, multiple myeloma, chronic lymphocytic leukemia, cancer pain, tumor metastasis, transplant organ rejection, scleroderma, ocular fibrosis, age related macular degeneration (AMD), diabetic retinopathy, collagen vascular disease, atherosclerosis, Raynaud’s phenomenon, or neuropathic pain in a mammal ccomprising administering a therapeutically effective amount of a compound of the present invention, or
  • treating cover the treatment of a disease-state in a mammal, particularly in a human, and include: (a) inhibiting the disease-state, i.e., arresting it development; and/or (b) relieving the disease-state, i.e., causing regression of the disease state.
  • treating or “treatment” also include the protective treatment of a disease state to reduce and/or minimize the risk and/or reduction in the risk of recurrence of a disease state by administering to a patient a therapeutically effective amount of at least one of the compounds of the present invention or a or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof.
  • Patients may be selected for such protective therapy based on factors that are known to increase risk of suffering a clinical disease state compared to the general population.
  • For protective treatment conditions of the clinical disease state may or may not be presented yet.
  • the protective treatment can be divided into (a) primary prophylaxis and (b) secondary prophylaxis.
  • Primary prophylaxis is defined as treatment to reduce or minimize the risk of a disease state in a patient that has not yet presented with a clinical disease state
  • secondary prophylaxis is defined as minimizing or reducing the risk of a recurrence or second occurrence of the same or similar clinical disease state.
  • the present compounds can be isolated in optically active or racemic forms.
  • Optically active forms may be prepared by resolution of racemic forms or by synthesis from optically active starting materials. All processes used to prepare compounds of the present invention and intermediates made therein are considered to be part of the present invention.
  • enantiomeric or diastereomeric products When enantiomeric or diastereomeric products are prepared, they may be separated by conventional methods, for example, by chromatography or fractional crystallization.
  • the end products of the present invention are obtained either in free (neutral) or salt form. Both the free form and the salts of these end products are within the scope of the invention. If so desired, one form of a compound may be converted into another form.
  • a free base or acid may be converted into a salt; a salt may be converted into the free compound or another salt; a mixture of isomeric compounds of the present invention may be separated into the individual isomers.
  • Compounds of the present invention, free form and salts thereof, may exist in multiple tautomeric forms, in which hydrogen atoms are transposed to other parts of the molecules and the chemical bonds between the atoms of the molecules are consequently rearranged. It should be understood that all tautomeric forms, insofar as they may exist, are included within the invention.
  • stereoisomer refers to isomers of identical constitution that differ in the arrangement of their atoms in space. Enantiomers and diastereomers are examples of stereoisomers.
  • enantiomer refers to one of a pair of molecular species that are mirror images of each other and are not superimposable.
  • diastereomer refers to stereoisomers that are not mirror images.
  • racemate or “racemic mixture” refers to a composition composed of equimolar quantities of two enantiomeric species, wherein the composition is devoid of optical activity.
  • R and S represent the configuration of substituents around a chiral carbon atom(s).
  • the isomeric descriptors “R” and “S” are used as described herein for indicating atom configuration(s) relative to a core molecule and are intended to be used as defined in the literature (IUPAC Recommendations 1996, Pure and Applied Chemistry , 68:2193-2222 (1996)).
  • chiral refers to the structural characteristic of a molecule that makes it impossible to superimpose it on its mirror image.
  • homochiral refers to a state of enantiomeric purity.
  • optical activity refers to the degree to which a homochiral molecule or nonracemic mixture of chiral molecules rotates a plane of polarized light.
  • alkyl or “alkylene” is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. While“alkyl” denotes a monovalent saturated aliphatic radical (such as ethyl),“alkylene” denotes a bivalent saturated aliphatic radical (such as ethylene). For example, “C 3 to C l0 alkyl” or “C 3-l0 alkyl” is intended to include C 3 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , and C l0 alkyl groups.
  • C 3 to C l0 alkylene or "C 3-l0 alkylene" is intended to include C 3 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , and C l0 alkylene groups.
  • C 3 to C 6 alkyl or “C 3-6 alkyl” denotes alkyl having 1 to 6 carbon atoms; and “C 3 to C 6 alkylene” or “C 3-6 alkylene” denotes alkylene having 1 to 6 carbon atoms; and “C ⁇ to C 4 alkyl” or “C ] -4 alkyl” denotes alkyl having 1 to 4 carbon atoms; and “C ⁇ to C 4 alkylene” or “C l-4 alkylene” denotes alkylene having 1 to 4 carbon atoms.
  • Alkyl group can be unsubstituted or substituted with at least one hydrogen being replaced by another chemical group.
  • Example alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (e.g ., n-propyl and isopropyl), butyl (e.g, n-butyl, isobutyl, /-butyl), and pentyl (e.g, n-pentyl, isopentyl, neopentyl).
  • Me methyl
  • Et ethyl
  • propyl e.g ., n-propyl and isopropyl
  • butyl e.g, n-butyl, isobutyl, /-butyl
  • pentyl e.g, n-pentyl, isopentyl, neopentyl
  • alkyl by itself or as part of another group, such as alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, alkoxyalkyl, haloalkoxyalkyl, and haloalkoxy, can be an alkyl having 1 to 4 carbon atoms, or 1 to 6 carbon atoms, or 1 to 10 carbon atoms.
  • Heteroalkyl refers to an alkyl group where one or more carbon atoms have been replaced with a heteroatom, such as, O, N, or S.
  • a heteroatom e.g, O, N, or S
  • the resulting heteroalkyl groups are, respectively, an alkoxy group (e.g, -OCH 3 , etc.), an alkylamino (e.g, -NHCH3, -N(CH3) 2 , etc.), or a thioalkyl group (e.g, -SCH3).
  • heteroalkyl groups are, respectively, an alkyl ether (e.g, -CH2CH2-O-CH3, etc.), an alkylaminoalkyl
  • a terminal carbon atom of the alkyl group is replaced with a heteroatom (e.g, O, N, or S)
  • the resulting heteroalkyl groups are, respectively, a hydroxyalkyl group (e.g, -CH2CH2-OH), an aminoalkyl group (e.g, -CH2NH2), or an alkyl thiol group (e.g, -CH2CH2-SH).
  • a heteroalkyl group can have, for example, 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms.
  • a Ci-C 6 heteroalkyl group means a heteroalkyl group having 1 to 6 carbon atoms.
  • alkenyl or “alkenyl ene” is intended to include hydrocarbon chains of either straight or branched configuration having the specified number of carbon atoms and one or more, preferably one to two, carbon-carbon double bonds that may occur in any stable point along the chain.
  • C2 to C 6 alkenyl or “C2-6 alkenyl” (or alkenyl ene) is intended to include C2, C3, C 4 , C 5 , and C 6 alkenyl groups.
  • alkenyl examples include, but are not limited to, ethenyl, l-propenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-methyl-2- propenyl, and 4-methyl-3-pentenyl.
  • Alkynyl or “alkynylene” is intended to include hydrocarbon chains of either straight or branched configuration having one or more, preferably one to three, carbon- carbon triple bonds that may occur in any stable point along the chain.
  • C 2 to C 6 alkynyl or “C 2-6 alkynyl” (or alkynylene) is intended to include C 2 , C 3 , C 4 , C 5 , and C 6 alkynyl groups; such as ethynyl, propynyl, butynyl, pentynyl, and hexynyl.
  • “arylalkyl” (a.k.a. aralkyl),“heteroarylalkyl”“carbocyclylalkyl” or“heterocyclylalkyl” refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, is replaced with an aryl, heteroaryl, carbocyclyl, or heterocyclyl radical, respectively.
  • Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-l-yl, naphthylmethyl, 2- naphthylethan-l-yl, naphthobenzyl, 2-naphthophenylethan-l-yl and the like.
  • the arylalkyl, heteroarylalkyl, carbocyclylalkyl, or heterocyclylalkyl group can comprise 4 to 20 carbon atoms and 0 to 5 heteroatoms, e.g ., the alkyl moiety may contain 1 to 6 carbon atoms.
  • “Benzyl” can also be represented by formula“Bn”.
  • alkoxy refers to an -O-alkyl group.
  • Ci to C 6 alkoxy or “Ci 6 alkoxy” (or alkyloxy) is intended to include Ci, C 2 , C 3 , C 4 , C 5 , and C 6 alkoxy groups.
  • Example alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), and /-butoxy.
  • alkylthio or “thioalkoxy” represents an alkyl group as defined above with the indicated number of carbon atoms attached through a sulphur bridge; for example, methyl-S- and ethyl -S-.
  • alkanoyl or“alkylcarbonyl” as used herein alone or as part of another group refers to alkyl linked to a carbonyl group.
  • alkylcarbonyl may be represented by alkyl-C(O)-.
  • C [ to Cg alkylcarbonyl” (or alkylcarbonyl) is intended to include C 3 , C 2 , C 3 , C 4 , C5, and Cg alkyl-C(O)- groups.
  • alkylsulfonyl or“sulfonamide” as used herein alone or as part of another group refers to alkyl or amino linked to a sulfonyl group.
  • alkylsulfonyl may be represented by -S(0) 2 R’, while sulfonamide may be represented by -S(0) 2 NR c R d .
  • R’ is C i to C 6 alkyl; and R c and R d are the same as defined below for “amino”.
  • carbamate as used herein alone or as part of another group refers to oxygen linked to an amido group.
  • carbamate may be represented by N(R c R d )-C(0)-0-, and R c and R d are the same as defined below for“amino”.
  • amido as used herein alone or as part of another group refers to amino linked to a carbonyl group.
  • amido may be represented by N(R c R d )-C(0)-, and R c and R d are the same as defined below for“amino”.
  • amino is defined as -NR cl R c2 , wherein R cl and R c2 are independently H or Ci- 6 alkyl; or alternatively, R cl and R c2 , taken together with the atoms to which they are attached, form a 3- to 8-membered heterocyclic ring which is optionally substituted with one or more group selected from halo, cyano, hydroxyl, amino, oxo, Ci- 6 alkyl, alkoxy, and aminoalkyl.
  • R cl or R c2 (or both of them) is Ci- 6 alkyl
  • the amino group can also be referred to as alkylamino.
  • alkylamino group include, without limitation, methylamino, ethylamino, propylamino, isopropylamino and the like. In one embodiment, amino is -NH 2 .
  • aminoalkyl refers to an alkyl group on which one of the hydrogen atoms is replaced by an amino group.
  • aminoalkyl may be represented by N(R cl R c2 )-alkylene-.
  • C ⁇ to Cg” or“Ci- 6 ” aminoalkyl” (or aminoalkyl) is intended to include C ⁇ , C 2 , C 3 , C 4 , C 5 , and C 6 aminoalkyl groups.
  • halogen or“halo” as used herein alone or as part of another group refers to chlorine, bromine, fluorine, and iodine, with chlorine or fluorine being preferred.
  • Haloalkyl is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with one or more halogens.
  • C ⁇ to C 6 haloalkyl or “C ⁇ g haloalkyl” (or haloalkyl) is intended to include C ⁇ , C 2 , C 3 , C 4 , C 5 , and C 6 haloalkyl groups.
  • Examples of haloalkyl include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl,
  • haloalkyl also include "fluoroalkyl” that is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more fluorine atoms.
  • polyhaloalkyl refers to an “alkyl” group as defined above which includes from 2 to 9, preferably from 2 to 5, halo substituents, such as F or Cl, preferably F, such as polyfluoroalkyl, for example, CF 3 CH 2 , CF 3 or CF3CF2CH2.
  • Haloalkoxy or "haloalkyloxy” represents a haloalkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge.
  • C ⁇ to Cg haloalkoxy or “C ⁇ g haloalkoxy”
  • C ⁇ g haloalkoxy is intended to include C ⁇ , C2, C3, C4, C5, and Cg haloalkoxy groups.
  • Examples of haloalkoxy include, but are not limited to, trifluoromethoxy, 2,2,2-trifluoroethoxy, and pentafluorothoxy.
  • haloalkoxy include, but are not limited to, trifluoromethoxy, 2,2,2-trifluoroethoxy, and pentafluorothoxy.
  • haloalkylthio or “thiohaloalkoxy” represents a haloalkyl group as defined above with the indicated number of carbon atoms attached through a sulphur bridge; for example trifluoromethyl-S-, and pentafluoroethyl-S-.
  • the term“polyhaloalkyloxy” as used herein refers to an“alkoxy” or“alkyloxy” group as defined above which includes from 2 to 9, preferably from 2 to 5, halo substituents, such as F or Cl, preferably F, such as polyfluoroalkoxy, for example, CF 3 CH 2 O, CF 3 O or CF 3 CF 2 CH 2 O.
  • Hydroalkyl is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more hydroxyl (OH).
  • C ⁇ to Cg hydroxyalkyl (or hydroxyalkyl), is intended to include C ⁇ , C2, C3, C4, C5, and Cg hydroxyalkyl groups.
  • cycloalkyl refers to cyclized alkyl groups, including mono-, bi- or poly-cyclic ring systems.
  • C 3 to C 8 cycloalkyl or “C 3-8 cycloalkyl” is intended to include C 3 , C 4 , C 5 , C 6 , C 7, and C 8 cycloalkyl groups, including monocyclic, bicyclic, and polycyclic rings.
  • Example cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and norbomyl.
  • Branched cycloalkyl groups such as 1 -methyl cyclopropyl and 2-methyl cyclopropyl and spiro and bridged cycloalkyl groups are included in the definition of "cycloalkyl”.
  • cycloheteroalkyl refers to cyclized heteroalkyl groups, including mono-, bi- or poly-cyclic ring systems. "C3 to C 7 cycloheteroalkyl” or "C3.7
  • cycloheteroalkyl is intended to include C3, C4, C5, Cg, and C 7 cycloheteroalkyl groups.
  • Example cycloheteroalkyl groups include, but are not limited to, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, and piperazinyl.
  • Branched cycloheteroalkyl groups such as piped dinylmethyl, piperazinylmethyl, morpholinylmethyl, pyridinylmethyl, pyridizylmethyl,
  • carrier As used herein, “carbocycle”, “carbocyclyl” or “carbocyclic residue” is intended to mean any stable 3-, 4-, 5-, 6-, 7-, or 8-membered monocyclic or bicyclic or 7-, 8-, 9-, 10-, 11-, 12-, or l3-membered bicyclic or tricyclic hydrocarbon ring, any of which may be saturated, partially unsaturated, unsaturated or aromatic.
  • carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptenyl, cycloheptyl, cycloheptenyl, adamantyl, cyclooctyl, cyclooctenyl, cyclooctadienyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, anthracenyl, and tetrahydronaphthyl (tetralin).
  • bridged rings are also included in the definition of carbocycle (e.g ., [2.2.2]bicyclooctane).
  • carbocycles e.g ., [2.2.2]bicyclooctane.
  • Preferred carbocycles are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, and indanyl.
  • carbocyclyl When the term “carbocyclyl” is used, it is intended to include “aryl”.
  • a bridged ring occurs when one or more carbon atoms link two non- adjacent carbon atoms.
  • Preferred bridges are one or two carbon atoms. It is noted that a bridge always converts a monocyclic ring into a tricyclic ring. When a ring is bridged, the substituents recited for the ring may also be present on the bridge.
  • the term“carbocyclyl”, including“cycloalkyl” and“cycloalkenyl”, as employed herein alone or as part of another group includes saturated or partially unsaturated (containing 1 or 2 double bonds) cyclic hydrocarbon groups containing 1 to 3 rings, including monocyclicalkyl, bicyclicalkyl and tricyclicalkyl, containing a total of 3 to 20 carbons forming the rings, preferably 3 to 10 carbons or 3 to 6 carbons, forming the ring and which may be fused to 1 or 2 aromatic rings as described for aryl, which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl, cyclohexenyl,
  • any of which groups may be optionally substituted with 1 to 4 substituents such as halogen, alkyl, alkoxy, hydroxy, aryl, aryloxy, arylalkyl, cycloalkyl, alkylamido, alkanoyl amino, oxo, acyl, arylcarbonylamino, nitro, cyano, thiol and/or alkylthio and/or any of the alkyl substituents.
  • substituents such as halogen, alkyl, alkoxy, hydroxy, aryl, aryloxy, arylalkyl, cycloalkyl, alkylamido, alkanoyl amino, oxo, acyl, arylcarbonylamino, nitro, cyano, thiol and/or alkylthio and/or any of the alkyl substituents.
  • bicyclic carbocyclyl or "bicyclic carbocyclic group” is intended to mean a stable 9- or lO-membered carbocyclic ring system that contains two fused rings and consists of carbon atoms. Of the two fused rings, one ring is a benzo ring fused to a second ring; and the second ring is a 5- or 6-membered carbon ring which is saturated, partially unsaturated, or unsaturated.
  • the bicyclic carbocyclic group may be attached to its pendant group at any carbon atom which results in a stable structure.
  • the bicyclic carbocyclic group described herein may be substituted on any carbon if the resulting compound is stable.
  • bicyclic carbocyclic group examples include naphthyl, l,2-dihydronaphthyl, l,2,3,4-tetrahydronaphthyl, and indanyl.
  • aryl refers to monocyclic or polycyclic (including bicyclic and tricyclic) aromatic hydrocarbons, including, for example, phenyl, naphthyl, anthracenyl, and phenanthranyl.
  • Aryl moieties are well known and described, for example, in Lewis, R.J., ed., Hawley's Condensed Chemical Dictionary , 13th Edition, John Wiley & Sons, Inc., New York (1997).
  • aryl denotes monocyclic and bicyclic aromatic groups containing 6 to 10 carbons in the ring portion (such as phenyl or naphthyl including l-naphthyl and 2-naphthyl).
  • aryl Cg or C 3 o aryl or “Cg-io aryl” refers to phenyl and naphthyl.
  • aryl Cg or C m aryl
  • C 6 -io aryl or “aromatic residue” may be unsubstituted or substituted with 1 to 5 groups, preferably 1 to 3 groups, selected from -OH, -OCH 3 , -Cl, -F, -Br, -I, -CN,
  • heterocycle As used herein, the term “heterocycle”, “heterocyclyl”, or “heterocyclic group” is intended to mean a stable 3-, 4-, 5-, 6-, or 7-membered monocyclic or 5-, 6-, 7-, 8-, 9-,
  • heterocyclyl or “heterocyclic group” includes non-aromatic ring systems, such as heterocycloalkyl and heterocycloalkenyl.
  • the nitrogen and sulfur heteroatoms may optionally be oxidized ⁇ i.e., N 0 and S(0)p, wherein p is 0, 1 or 2).
  • the nitrogen atom may be substituted or unsubstituted (i.e., N or NR wherein R is H or another substituent, if defined).
  • the heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure.
  • the heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable.
  • a nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1.
  • hetercyclyl include, without limitation, azetidinyl, piperazinyl, piperidinyl, piperidonyl, piperonyl, pyranyl, morpholinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, morpholinyl, dihydrofuro[2,3-Z>]tetrahydrofuran.
  • bicyclic heterocycle or "bicyclic heterocyclic group” is intended to mean a stable 9- or lO-membered heterocyclic ring system which contains two fused rings and consists of carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from N, O and S. Of the two fused rings, one ring is a 5- or 6-membered monocyclic aromatic ring comprising a 5-membered heteroaryl ring, a 6-membered heteroaryl ring or a benzo ring, each fused to a second ring.
  • the second ring is a 5- or 6-membered monocyclic ring which is saturated, partially unsaturated, or unsaturated, and comprises a 5-membered heterocycle, a 6-membered heterocycle or a carbocycle (provided the first ring is not benzo when the second ring is a carbocycle).
  • the bicyclic heterocyclic group may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure.
  • the bicyclic heterocyclic group described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1. Examples of a bicyclic heterocyclic group are, but not limited to,
  • Bridged rings are also included in the definition of heterocycle.
  • a bridged ring occurs when one or more atoms (i.e., C, O, N, or S) link two non-adjacent carbon or nitrogen atoms.
  • Examples of bridged rings include, but are not limited to, one carbon atom, two carbon atoms, one nitrogen atom, two nitrogen atoms, and a carbon-nitrogen group. It is noted that a bridge always converts a monocyclic ring into a tricyclic ring. When a ring is bridged, the substituents recited for the ring may also be present on the bridge.
  • heteroaryl is intended to mean stable monocyclic and polycyclic (including bicyclic and tricyclic) aromatic hydrocarbons that include at least one heteroatom ring member such as sulfur, oxygen, or nitrogen.
  • Heteroaryl groups include, without limitation, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrroyl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, l,2,4-thiadiazolyl, isothiazolyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, benzodi
  • Heteroaryl groups are substituted or unsubstituted.
  • the nitrogen atom is substituted or unsubstituted (i.e., N or NR wherein R is H or another substituent, if defined).
  • the nitrogen and sulfur heteroatoms may optionally be oxidized (i.e., N 0 and S(0)p, wherein p is 0, 1 or 2).
  • heteroaryl also include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl,
  • benzisothiazolyl benzimidazolinyl, carbazolyl, 4a//-carbazolyf carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H- ⁇ ,5,2-dithiazinyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1 //-indazolyl, imidazolopyridinyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isatinoyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isothiazolopyridinyl, isoxazolyl, iso
  • thiazolyl thienyl, thiazolopyridinyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, l,2,3-triazolyl, l,2,4-triazolyl, l,2,5-triazolyl, l,3,4-triazolyl, and xanthenyl.
  • Examples of 5- to lO-membered heteroaryl include, but are not limited to, pyridinyl, furanyl, thienyl, pyrazolyl, imidazolyl, imidazolidinyl, indolyl, tetrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, oxazolidinyl, thiadiazinyl, thiadiazolyl, thiazolyl, triazinyl, triazolyl, benzimidazolyl, l//-indazolyl, benzofuranyl, benzothiofuranyl, benztetrazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, oxindolyl, benzoxazolinyl, benzthiazolyl, benzisothiazolyl, isatinoyl, isoquinolinyl, octahydro
  • 6-membered heteroaryl include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrazinyl, imidazolyl, imidazolidinyl, indolyl, tetrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, oxazolidinyl, thiadiazinyl, thiadiazolyl, thiazolyl, triazinyl, and triazolyl.
  • the heteroaryl are selected from benzthiazolyl, imidazolpyridinyl, pyrrol opyridinyl, quinolinyl, and indolyl.
  • Carbocyclyl or “heterocyclyl” includes one to three additional rings fused to the carbocyclic ring or the heterocyclic ring (such as aryl, cycloalkyl, heteroaryl or cycloheteroalkyl rings), for example,
  • alkylaminocarbonyl arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl,
  • alkylcarbonyloxy aryl carbonyl oxy, alkylcarbonylamino, arylcarbonylamino, arylsulfmyl, arylsulfmylalkyl, arylsulfonylamino and arylsulfonaminocarbonyl and/or any of the alkyl substituents set out herein.
  • alkyl alkenyl, alkynyl, cycloalkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl
  • the number of carbon atoms and ring members are the same as those defined in the terms by themselves.
  • alkoxy, haloalkoxy, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, haloalkoxy, alkoxyalkoxy, haloalkylamino, alkoxyalkylamino, haloalkoxyalkylamino, alkylthio, and the like each independently contains the number of carbon atoms which are the same as defined for the term“alkyl”, such as 1 to 4 carbon atoms, 1 to 6 carbon atoms, 1 to 10 carbon atoms, etc.
  • cycloalkoxy, heterocyclyl oxy each independently contains the number of carbon atoms which are the same as defined for the term“alkyl”, such as 1 to 4 carbon atoms, 1 to 6 carbon atoms, 1 to 10 carbon atoms, etc.
  • each indepdent ly contains ring members which are the same as defined for the terms“cycloalkyl”,“heterocyclyl”,“aryl”, and “heteroaryl”, such as 3 to 6-membered, 4 to 7-membered, 6 to lO-membered, 5 to 10- membered, 5 or 6-membered, etc.
  • a bond pointing to a bold line depicts the bond that is the point of attachment of the moiety or substituent to the core or backbone structure.
  • the enantiomers individually, such as x L Y or x .L Y . , as well as a racemic mixture thereof.
  • a carbocyclic or heterocyclic moiety may be bonded or otherwise attached to a designated substrate through differing ring atoms without denoting a specific point of attachment, then all possible points are intended, whether through a carbon atom or, for example, a trivalent nitrogen atom.
  • pyridyl means 2-, 3- or 4-pyridyl
  • thienyl means 2- or 3-thienyl
  • substituents and other moieties of the compounds of the present invention should be selected in order to provide a compound which is sufficiently stable to provide a pharmaceutically useful compound which can be formulated into an acceptably stable pharmaceutical composition.
  • Compounds of the present invention which have such stability are contemplated as falling within the scope of the present invention.
  • counter ion is used to represent a negatively charged species such as chloride, bromide, hydroxide, acetate, and sulfate.
  • metal ion refers to alkali metal ions such as sodium, potassium or lithium and alkaline earth metal ions such as magnesium and calcium, as well as zinc and aluminum.
  • substituted means that at least one hydrogen atom (attached to carbon atom or heteroatom) is replaced with a non-hydrogen group, provided that normal valencies are maintained and that the substitution results in a stable compound.
  • 2 hydrogens on the atom are replaced.
  • Oxo substituents are not present on aromatic moieties.
  • a ring system e.g ., carbocyclic or heterocyclic
  • the term“substituted” in reference to alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, alkylene, aryl, arylalkyl, heteroaryl, heteroarylalkyl, carbocyclyl, and heterocyclyl means alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, alkylene, aryl, arylalkyl, heteroaryl, heteroarylalkyl, carbocyclyl, and heterocyclyl, respectively, in which one or more hydrogen atoms, which are attached to either carbon or heteroatom, are each independently replaced with one or more non hydrogen substituent(s).
  • nitrogen atoms ⁇ e.g, amines
  • these may be converted to N-oxides by treatment with an oxidizing agent ⁇ e.g, mCPBA and/or hydrogen peroxides) to afford other compounds of this invention.
  • an oxidizing agent ⁇ e.g, mCPBA and/or hydrogen peroxides
  • shown and claimed nitrogen atoms are considered to cover both the shown nitrogen and its N-oxide (N— >0) derivative.
  • any variable occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence.
  • a group is shown to be substituted with 0, 1, 2, or 3 R groups, then said group be unsubstituted when it is substituted with 0 R group, or be substituted with up to three R groups, and at each occurrence R is selected independently from the definition of R.
  • tautomer refers to each of two or more isomers of a compound that exist together in equilibrium, and are readily interchanged by migration of an atom or group within the molecule
  • 1,2, 3 -triazole exists in two tautomeric forms as defined above:
  • this disclosure is intended to cover all possible tautomers even when a structure depicts only one of them.
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, and/or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • the compounds of the present invention can be present as salts, which are also within the scope of this invention.
  • Pharmaceutically acceptable salts are preferred.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound that contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences ,
  • the compounds of the present invention can form acid addition salts. These are formed, for example, with strong inorganic acids, such as mineral acids, for example sulfuric acid, phosphoric acid or a hydrohalic acid, with organic carboxylic acids, such as alkanecarboxylic acids of 1 to 4 carbon atoms, for example acetic acid, which are unsubstituted or substituted, for example, by halogen as chloroacetic acid, such as saturated or unsaturated dicarboxylic acids, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or terephthalic acid, such as hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or citric acid, such as amino acids, (for example aspartic or glutamic acid or lysine or arginine), or benzoic acid, or with organic sulfonic acids, such as (Ci-C 4 )
  • Corresponding acid addition salts can also be formed having, if desired, an additionally present basic center.
  • the compounds of the present invention having at least one acid group can also form salts with bases.
  • Suitable salts with bases are, for example, metal salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium or magnesium salts, or salts with ammonia or an organic amine, such as morpholine, thiomorpholine, piperidine, pyrrolidine, a mono, di or tri-lower alkylamine, for example ethyl, tert-butyl, diethyl, diisopropyl, triethyl, tributyl or dimethyl -propylamine, or a mono, di or trihydroxy lower alkylamine, for example mono, di or triethanolamine.
  • Corresponding internal salts may furthermore be formed. Salts which are unsuitable for pharmaceutical uses but which can be employed, for example, for the isolation or purification of free compounds
  • Preferred salts of the compounds of Formula (I) which contain a basic group include monohydrochloride, hydrogensulfate, methanesulfonate, phosphate, nitrate or acetate.
  • Preferred salts of the compounds of Formula (I) which contain an acid group include sodium, potassium and magnesium salts and pharmaceutically acceptable organic amines.
  • compounds of Formula (I) may have prodrug forms. Any compound that will be converted in vivo to provide the bioactive agent (i.e., a compound of formula I) is a prodrug within the scope and spirit of the invention.
  • a prodrug within the scope and spirit of the invention.
  • Various forms of prodrugs are well known in the art. For examples of such prodrug derivatives, see:
  • Bundgaard, FL ed., Design of Prodrugs, Elsevier (1985), and Widder, K. et ak, eds., Methods in Enzymology , 112:309-396, Academic Press (1985);
  • Bundgaard, H. Chapter 5, “Design and Application of Prodrugs", A Textbook of Drug Design and Development, pp. 113-191, Krosgaard-Larsen, P. et al., eds., Harwood Academic Publishers (1991);
  • the compounds of the present invention contain a carboxy group which can form physiologically hydrolyzable esters that serve as prodrugs, i.e.,“prodrug esters”, by being hydrolyzed in the body to yield the compounds of the present invention per se.
  • physiologically hydrolyzable esters of compounds of the present invention include C ] to Cg alkyl, C ] to Cg alkylbenzyl, 4-methoxybenzyl, indanyl, phthalyl, methoxymethyl, C j _6 alkanoyloxy-C ] _g alkyl (e.g, acetoxym ethyl, pivaloyloxym ethyl or
  • esters may be prepared by conventional techniques known in the art.
  • The“prodrug esters” can be formed by reacting the carboxylic acid moiety of the compounds of the present invention with either alkyl or aryl alcohol, halide, or sulfonate employing procedures known to those skilled in the art. Such esters may be prepared by conventional techniques known in the art.
  • prodrugs Preparation of prodrugs is well known in the art and described in, for example, King, F.D., ed., Medicinal Chemistry: Principles and Practice, The Royal Society of Chemistry, Cambridge, UK (1994); Testa, B. et al., Hydrolysis in Drug and Prodrug Metabolism. Chemistry, Biochemistry and Enzymology, VCHA and Wiley -VCH, Zurich, Switzerland (2003); Wermuth, C.G., ed., The Practice of Medicinal Chemistry, Academic Press, San Diego, CA (1999).
  • the present invention is intended to include all isotopes of atoms occurring in the present compounds.
  • Isotopes include those atoms having the same atomic number but different mass numbers.
  • isotopes of hydrogen include deuterium and tritium.
  • Deuterium has one proton and one neutron in its nucleus and that has twice the mass of ordinary hydrogen.
  • Deuterium can be represented by symbols such as " 2 H” or "D”.
  • Isotopes of carbon include 13 C and 14 C.
  • Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed. Such compounds have a variety of potential uses, e.g ., as standards and reagents in determining the ability of a potential
  • “Stable compound” and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent. It is preferred that compounds of the present invention do not contain a N-halo, S(0) 2 H, or S(0)H group.
  • solvate means a physical association of a compound of this invention with one or more solvent molecules, whether organic or inorganic. This physical association includes hydrogen bonding. In certain instances the solvate will be capable of isolation, for example, when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid.
  • the solvent molecules in the solvate may be present in a regular arrangement and/or a non-ordered arrangement.
  • the solvate may comprise either a stoichiometric or nonstoichiometric amount of the solvent molecules.
  • “Solvate” encompasses both solution-phase and isolable solvates. Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates. Methods of solvation are generally known in the art.
  • Lysophospholipids are membrane-derived bioactive lipid mediators.
  • Lysophospholipids include, but are not limited to, lysophosphatidic acid (l-acyl-2- hydroxy-s «-glycero-3 -phosphate; LPA), sphingosine 1 -phosphate (S1P),
  • LPC lysophosphatidylcholine
  • SPC sphingosylphosphorylcholine
  • Lysophospholipids affect fundamental cellular functions that include cellular
  • LPA acts through sets of specific G protein-coupled receptors (GPCRs) in an autocrine and paracrine fashion. LPA binding to its cognate GPCRs (LPAi, LPA 2 , LPA 3 , LPA 4 , LPA 5 , LPA 6 ) activates intracellular signaling pathways to produce a variety of biological responses.
  • GPCRs G protein-coupled receptors
  • Lysophospholipids such as LPA are quantitatively minor lipid species compared to their major phospholipid counterparts (e.g ., phosphatidylcholine,
  • LPA has a role as a biological effector molecule, and has a diverse range of physiological actions such as, but not limited to, effects on blood pressure, platelet activation, and smooth muscle contraction, and a variety of cellular effects, which include cell growth, cell rounding, neurite retraction, and actin stress fiber formation and cell migration.
  • the effects of LPA are predominantly receptor mediated.
  • LPAi LPA 2 , LPA3, LPA 4 , LPA5, LPA 6
  • LPA 6 LPA mediates a range of downstream signaling cascades.
  • LPAi mitogen-activated protein kinase
  • AC adenylyl cyclase
  • PLC phospholipase C
  • LPA receptor activation include, but are not limited to, cyclic adenosine monophosphate (cAMP), cell division cycle 42/GTP -binding protein (Cdc42) , proto-oncogene serine/threonine-protein kinase Raf (c-RAF), proto- oncogene tyrosine-protein kinase Src (c-src), extracellular signal-regulated kinase (ERK), focal adhesion kinase (FAK), guanine nucleotide exchange factor (GEF), glycogen synthase kinase 3b (GSK3b), c-jun amino-terminal kinase (INK), MEK, myosin light chain II (MLC II), nuclear factor kB (NF-kB), N-methyl-D-aspartate (NMDA) receptor activation, phosphatidylinositol 3-kinase (PI3K), protein cyclic aden
  • the actual pathway and realized end point are dependent on a range of variables that include receptor usage, cell type, expression level of a receptor or signaling protein, and LPA concentration. Nearly all mammalian cells, tissues and organs co-express several LPA-receptor subtypes, which indicates that LPA receptors signal in a cooperative manner. LPAi, LPA 2 , and LPA 3 share high amino acid sequence similarity.
  • LPA is produced from activated platelets, activated adipocytes, neuronal cells, and other cell types. Serum LPA is produced by multiple enzymatic pathways that involve monoacylglycerol kinase, phospholipase Ai, secretory phospholipase A 2 , and
  • lysophospholipase D including autotaxin.
  • lysophospholipase D including autotaxin.
  • Several enzymes are involved in LPA degradation: lysophospholipase, lipid phosphate phosphatase, and LPA acyl transferase such as endophilin.
  • LPA concentrations in human serum are estimated to be 1-5 mM. Serum LPA is bound to albumin, low-density lipoproteins, or other proteins, which possibly protect LPA from rapid degradation.
  • LPA molecular species with different acyl chain lengths and saturation are naturally occurring, including l-palmitoyl (16:0), l-palmitoleoyl (16: 1), l-stearoyl (18:0), l-oleoyl (18: 1), l-linoleoyl (18:2), and 1- arachidonyl (20:4) LPA.
  • Quantitatively minor alkyl LPA has biological activities similar to acyl LPA, and different LPA species activate LPA receptor subtypes with varied efficacies.
  • LPAi (previously called VZG-l/EDG-2/mrecl.3) couples with three types of G proteins, Gi /0 , G q , and G12 / 13. Through activation of these G proteins, LPA induces a range of cellular responses through LPAi including but not limited to: cell proliferation, serum- response element (SRE) activation, mitogen-activated protein kinase (MAPK) activation, adenylyl cyclase (AC) inhibition, phospholipase C (PLC) activation, Ca 2+ mobilization, Akt activation, and Rho activation.
  • SRE serum- response element
  • MAPK mitogen-activated protein kinase
  • AC adenylyl cyclase
  • PLC phospholipase C
  • LPAi Wide expression of LPAi is observed in adult mice, with clear presence in testis, brain, heart, lung, small intestine, stomach, spleen, thymus, and skeletal muscle.
  • human tissues also express LPAi; it is present in brain, heart, lung, placenta, colon, small intestine, prostate, testis, ovary, pancreas, spleen, kidney, skeletal muscle, and thymus.
  • LPA 2 (EDG-4) also couples with three types of G proteins, Gi /0 , G q , and G 12/13 , to mediate LPA-induced cellular signaling.
  • Expression of LPA 2 is observed in the testis, kidney, lung, thymus, spleen, and stomach of adult mice and in the human testis, pancreas, prostate, thymus, spleen, and peripheral blood leukocytes.
  • Expression of LPA 2 is upregulated in various cancer cell lines, and several human LPA 2 transcriptional variants with mutations in the 3 '-untranslated region have been observed.
  • LPA 2 in mice has not shown any obvious phenotypic abnormalities, but has demonstrated a significant loss of normal LPA signaling (e.g ., PLC activation, Ca 2+ mobilization, and stress fiber formation) in primary cultures of mouse embryonic fibroblasts (MEFs).
  • LPA signaling e.g ., PLC activation, Ca 2+ mobilization, and stress fiber formation
  • MEFs mouse embryonic fibroblasts
  • LPAi contributes to normal LPA- mediated signaling responses in at least some cell types (Choi et al, Biochemica et Biophysica Acta 2008, 1781, p531-539).
  • LPA3 (EDG-7) is distinct from LPAi and LPA 2 in its ability to couple with Gi /0 and G q but not Go /13 and is much less responsive to LPA species with saturated acyl chains. LPA3 can mediate pleiotropic LPA-induced signaling that includes PLC activation, Ca 2+ mobilization, AC inhibition/activation, and MAPK activation.
  • LPA3 Overexpression of LPA3 in neuroblastoma cells leads to neurite elongation, whereas that of LPAi or LPA 2 results in neurite retraction and cell rounding when stimulated with LPA.
  • Expression of LPA 3 is observed in adult mouse testis, kidney, lung, small intestine, heart, thymus, and brain. In humans, it is found in the heart, pancreas, prostate, testis, lung, ovary, and brain (frontal cortex, hippocampus, and amygdala).
  • LPA 4 (p2y 9 /GPR23) is of divergent sequence compared to LPAi, LPA 2 , and LPA 3 with closer similarity to the platelet-activating factor (PAF) receptor.
  • LPA 4 mediates LPA induced Ca 2+ mobilization and cAMP accumulation, and functional coupling to the G protein Gs for AC activation, as well as coupling to other G proteins.
  • the LPA 4 gene is expressed in the ovary, pancreas, thymus, kidney and skeletal muscle.
  • LPA (GPR92) is a member of the purinocluster of GPCRs and is structurally most closely related to LPA 4 .
  • LPA 5 is expressed in human heart, placenta, spleen, brain, lung and gut. LPA 5 also shows very high expression in the CD8+ lymphocyte
  • LPA 6 (p2y5) is a member of the purinocluster of GPCRs and is structurally most closely related to LPA 4.
  • LPA 6 is an LPA receptor coupled to the Gl2/l3-Rho signaling pathways and is expressed in the inner root sheaths of human hair follicles.
  • Normal wound healing occurs by a highly coordinated sequence of events in which cellular, soluble factors and matrix components act in concert to repair the injury.
  • the healing response can be described as taking place in four broad, overlapping phases— hemostasis, inflammation, proliferation, and remodeling.
  • Many growth factors and cytokines are released into a wound site to initiate and perpetuate wound healing processes.
  • LPA is one such mediator that is released from activated platelets; this induces platelet aggregation along with mitogenic/migration effects on the surrounding cells, such as endothelial cells, smooth muscle cells, fibroblasts, and keratinocytes.
  • Topical application of LPA to cutaneous wounds in mice promotes repair processes (wound closure and increased neoepithelial thickness) by increasing cell proliferation/ migration without affecting secondary inflammation.
  • ECM dermal extracellular matrix
  • LPA regulates many important functions of fibroblasts in wound healing, including proliferation, migration, differentiation and contraction. Fibroblast proliferation is required in wound healing in order to fill an open wound. In contrast, fibrosis is characterized by intense proliferation and accumulation of myofibroblasts that actively synthesize ECM and proinflammatory cytokines. LPA can either increase or suppress the proliferation of cell types important in wound healing, such as epithelial and endothelial cells (EC), macrophages, keratinocytes, and fibroblasts.
  • EC epithelial and endothelial cells
  • a role for LPAi in LPA-induced proliferation was provided by the observation that LPA-stimulated proliferation of fibroblasts isolated from LPAi receptor null mice was attenuated (Mills et al , Nat Rev. Cancer 2003; 3: 582-591). LPA induces cytoskeletal changes that are integral to fibroblast adhesion, migration, differentiation and contraction.
  • Tissue injury initiates a complex series of host wound-healing responses; if successful, these responses restore normal tissue structure and function. If not, these responses can lead to tissue fibrosis and loss of function.
  • fibrosis For the majority of organs and tissues the development of fibrosis involves a multitude of events and factors. Molecules involved in the development of fibrosis include proteins or peptides (profibrotic cytokines, chemokines, metalloproteinases etc.) and phospholipids. Phospholipids involved in the development of fibrosis include platelet activating factor (PAF), phosphatidyl choline, sphingosine-l phosphate (S1P) and lysophosphatidic acid (LPA).
  • PAF platelet activating factor
  • S1P phosphatidyl choline
  • S1P sphingosine-l phosphate
  • LPA lysophosphatidic acid
  • CTGF connective tissue growth factor
  • LPA is associated with the progression of liver fibrosis.
  • LPA induces stellate cell and hepatocyte proliferation. These activated cells are the main cell type responsible for the accumulation of ECM in the liver.
  • LPA plasma levels rise during CCL-induced liver fibrosis in rodents, or in hepatitis C virus-induced liver fibrosis in humans (N. Watanabe, et al ., Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity, Life Sci. 81 (2007) 1009-1015; N.Watanabe, et al., J. Clin. Gastroenterol . 41 (2007) 616-623).
  • LPA is associated with heart disease and mycocardial remodeling. Serum LPA levels are increased after myocardial infarction in patients and LPA stimulates rat cardiac fibroblast proliferation and collagen production ( Chen et al. FEBSLett. 2006 Aug
  • Fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF) are associated with high morbidity and mortality.
  • LPA is an important mediator of fibroblast recruitment in pulmonary fibrosis.
  • chemoattractant activity plays an important role in the lungs in patients with pulmonary fibrosis.
  • Profibrotic effects of LPAi-receptor stimulation is explained by LPAi-receptor- mediated vascular leakage and increased fibroblast recruitment, both profibrotic events.
  • the LPA-LPAi pathway has a role in mediating fibroblast migration and vascular leakage in IPF. The end result is the aberrant healing process that characterizes this fibrotic condition.
  • the LPAi receptor is the LPA receptor most highly expressed on fibroblasts obtained from patients with IPF. Furthermore, BAL obtained from IPF patients induced chemotaxis of human foetal lung fibroblasts that was blocked by the dual LPAi- LPAi receptor antagonist Ki 16425. In an experimental bleomycin-induced lung injury mouse model, it was shown that LPA levels were high in bronchoalveolar lavage samples compared with unexposed controls. LPAi knockout mice are protected from fibrosis after bleomycin challenge with reduced fibroblast accumulation and vascular leakage. In human subjects with IPF, high LPA levels were observed in bronchoalveolar lavage samples compared with healthy controls.
  • the LPA-LPAi pathway is crucial in fibroblast recruitment and vascular leakage in pulmonary fibrosis.
  • LPA induces or ⁇ 6-mediated TGF-b activation on human lung epithelial cells ⁇ Xu et al. Am. J. Pathology, 2009, 174, 1264-1279).
  • the LPA-induced o ⁇ 6-mediated TGF-b activation is mediated by the LPA 2 receptor. Expression of the LPA 2 receptor is increased in epithelial cells and mesenchymal cells in areas of lung fibrosis from IPF patients compared to normal human lung tissue.
  • the LPA-LPA 2 pathway contributes to the activation of the TGF-b pathway in pulmonary fibrosis.
  • compounds that inhibit LPA 2 show efficacy in the treatment of lung fibrosis.
  • compounds that inhibit both LPAi and LPA 2 show improved efficacy in the treatment of lung fibrosis compared to compounds which inhibit only LPAi or LPA 2.
  • the LPAi antagonist BMS-986020 was shown to significantly reduce the rate of FVC (forced vital capacity) decline in a 26-week clinical trial in IPF patients (Palmer et al., Chest , 2018, 154 , 1061-1069).
  • LPA and LPAi are involved in the etiology of kidney fibrosis.
  • LPA has effects on both proliferation and contraction of glomerular mesangial cells and thus has been implicated in proliferative glomerulonephritis (C.N. Inoue, et al., Clin. Sci. (Colch.) 1999, 96, 431-436).
  • UUO unilateral ureteral obstruction
  • LPA can participate in intraperitonial accumulation of monocyte/macrophages and LPA can induce expression of the profibrotic cytokine CTGF in primary cultures of human fibroblasts (J.S. Koh ,et al., ./. Clin. Invest., 1998, 102, 716-727).
  • CTGF plays a crucial role in UUO- induced tubulointerstitial fibrosis (TIF), and is involved in the profibrotic activity of TGFp This induction was almost completely suppressed by co-treatment with the LPA- receptor antagonist Ki 16425.
  • the profibrotic activity of LPA in kidney results from a direct action of LPA on kidney cells involving induction of CTGF.
  • LPA is implicated in liver disease and fibrosis. Plasma LPA levels and serum autotaxin (enzyme responsible for LPA production) are elevated in hepatitis patients and animal models of liver injury in correlation with increased fibrosis. LPA also regulates liver cell function. LPAi and LPA 2 receptors are expressed by mouse hepatic stellate cells and LPA stimulates migration of hepatic myofibroblasts.
  • LPA is in involved in wound healing in the eye.
  • LPAi and LPA 3 receptors are detectable in the normal rabbit corneal epithelial cells, keratocytes and endothelial cells and LPAi and LPAi expression are increased in corneal epithelial cells following injury.
  • LPA and its homologues are present in the aqueous humor and the lacrimal gland fluid of the rabbit eye and these levels are increased in a rabbit corneal injury model.
  • LPA induces actin stress fiber formation in rabbit corneal endothelial and epithelial cells and promotes contraction corneal fibroblasts. LPA also stimulates proliferation of human retinal pigmented epithelial cells
  • LPA is implicated in myocardial infarction and cardiac fibrosis. Serum LPA levels are increased in patients following mycocardial infarction (MI) and LPA stimulates proliferation and collagen production (fibrosis) by rat cardiac fibroblasts. Both LPA1 and LPA3 receptors are highly expressed in human heart tissue.
  • a compound of Formula (I), or a pharmaceutically acceptable salt thereof is used to treat or prevent fibrosis in a mammal.
  • a compound of Formulas (I), or a pharmaceutically acceptable salt thereof is used to treat fibrosis of an organ or tissue in a mammal.
  • a method for preventing a fibrosis condition in a mammal comprising administering to the mammal at risk of developing one or more fibrosis conditions a therapeutically effective amount of a compound of Formulas (I), or a pharmaceutically acceptable salt thereof.
  • the mammal has been exposed to one or more environmental conditions that are known to increase the risk of fibrosis of an organ or tissue.
  • the mammal has been exposed to one or more environmental conditions that are known to increase the risk of lung, liver or kidney fibrosis. In one aspect, the mammal has a genetic predisposition of developing fibrosis of an organ or tissue. In one aspect, a compound of Formula (I), or a
  • injury includes surgery.
  • fibrosis refers to conditions that are associated with the abnormal accumulation of cells and/or fibronectin and/or collagen and/or increased fibroblast recruitment and include but are not limited to fibrosis of individual organs or tissues such as the heart, kidney, liver, joints, lung, pleural tissue, peritoneal tissue, skin, cornea, retina, musculoskeletal and digestive tract.
  • Exemplary diseases, disorders, or conditions that involve fibrosis include, but are not limited to: Lung diseases associated with fibrosis, e.g ., idiopathic pulmonary fibrosis, pulmonary fibrosis secondary to systemic inflammatory disease such as rheumatoid arthritis, scleroderma, lupus, cryptogenic fibrosing alveolitis, radiation induced fibrosis, chronic obstructive pulmonary disease (COPD), scleroderma, chronic asthma, silicosis, asbestos induced pulmonary or pleural fibrosis, acute lung injury and acute respiratory distress (including bacterial pneumonia induced, trauma induced, viral pneumonia induced, ventilator induced, non-pulmonary sepsis induced, and aspiration induced); Chronic nephropathies associated with injury/fibrosis (kidney fibrosis), e.g. ,
  • glomerulonephritis secondary to systemic inflammatory diseases such as lupus and scleroderma, diabetes, glomerular nephritis, focal segmental glomerular sclerosis, IgA nephropathy, hypertension, allograft and Alport; Gut fibrosis, e.g. , scleroderma, and radiation induced gut fibrosis; Liver fibrosis, e.g.
  • cirrhosis alcohol induced liver fibrosis, nonalcoholic steatohepatitis (NASH), biliary duct injury, primary biliary cirrhosis, infection or viral induced liver fibrosis (e.g, chronic HCV infection), and autoimmune hepatitis; Head and neck fibrosis, e.g, radiation induced; Corneal scarring, e.g, LASIK (laser-assisted in situ keratomileusis), corneal transplant, and trabeculectomy;
  • NASH nonalcoholic steatohepatitis
  • biliary duct injury e.g, primary biliary cirrhosis, infection or viral induced liver fibrosis (e.g, chronic HCV infection), and autoimmune hepatitis
  • Head and neck fibrosis e.g, radiation induced
  • Corneal scarring e.g, LASIK (laser-assisted in situ keratomileusis), cornea
  • Hypertrophic scarring and keloids e.g ., bum induced or surgical
  • other fibrotic diseases e.g. , sarcoidosis, scleroderma, spinal cord injury/fibrosis, myelofibrosis, vascular restenosis, atherosclerosis, arteriosclerosis, Wegener's granulomatosis, mixed connective tissue disease, and Peyronie's disease.
  • a mammal suffering from one of the following non-limiting exemplary diseases, disorders, or conditions will benefit from therapy with a compound of Formula (I), or a pharmaceutically acceptable salt thereof: atherosclerosis, thrombosis, heart disease, vasculitis, formation of scar tissue, restenosis, phlebitis, COPD (chronic obstructive pulmonary disease), pulmonary hypertension, pulmonary fibrosis, pulmonary inflammation, bowel adhesions, bladder fibrosis and cystitis, fibrosis of the nasal passages, sinusitis, inflammation mediated by neutrophils, and fibrosis mediated by fibroblasts.
  • a compound of Formula (I), or a pharmaceutically acceptable salt thereof is administered to a mammal with fibrosis of an organ or tissue or with a predisposition of developing fibrosis of an organ or tissue with one or more other agents that are used to treat fibrosis.
  • the one or more agents include
  • the one or more agents include immunosuppressants. In one aspect, the one or more agents include B-cell antagonists. In one aspect, the one or more agents include uteroglobin.
  • a compound of Formula (I), or a pharmaceutically acceptable salt thereof is used to treat a dermatological disorders in a mammal.
  • dermatological disorder refers to a skin disorder.
  • Such dermatological disorders include, but are not limited to, proliferative or inflammatory disorders of the skin such as, atopic dermatitis, bullous disorders, collagenoses, psoriasis, scleroderma, psoriatic lesions, dermatitis, contact dermatitis, eczema, urticaria, rosacea, wound healing, scarring, hypertrophic scarring, keloids, Kawasaki Disease, rosacea, Sjogren-Larsso Syndrome, urticaria.
  • a compound of Formula (I), or a pharmaceutically acceptable salt thereof is used to treat systemic sclerosis. Pain
  • LPAi Since LPA is released following tissue injury, LPAi plays an important role in the initiation of neuropathic pain. LPAi, unlike LPA 2 or LPA-,, is expressed in both dorsal root ganglion (DRG) and dorsal root neurons. Using the antisense oligodeoxynucleotide (AS-ODN) for LPAi and LPAi-null mice, it was found that LPA-induced mechanical allodynia and hyperalgesia is mediated in an LPAi-dependent manner. LPAi and downstream Rho-ROCK activation play a role in the initiation of neuropathic pain signaling.
  • AS-ODN antisense oligodeoxynucleotide
  • LPA signaling appears to induce important neuropathic pain markers such as protein kinase C g (PKCy) and a voltage-gated calcium channel a2d1 subunit (Caa25l) in an LPAi and Rho-dependent manner (M. Inoue, et al ., Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling, Nat. Med. 10 (2004) 712-718).
  • PKCy protein kinase C g
  • Caa25l voltage-gated calcium channel a2d1 subunit
  • a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof is used in the treatment of pain in a mammal.
  • the pain is acute pain or chronic pain.
  • the pain is neuropathic pain.
  • a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof is used in the treatment of fibromylagia.
  • fibromyalgia stems from the formation of fibrous scar tissue in contractile (voluntary) muscles.
  • Fibrosis binds the tissue and inhibits blood flow, resulting in pain.
  • Lysophospholipid receptor signaling plays a role in the etiology of cancer.
  • Lysophosphatidic acid (LPA) and its G protein-coupled receptors (GPCRs) LPAi, LPA 2 , and/or LPA- play a role in the development of several types of cancers.
  • the initiation, progression and metastasis of cancer involve several concurrent and sequential processes including cell proliferation and growth, survival and anti-apoptosis, migration of cells, penetration of foreign cells into defined cellular layers and/or organs, and promotion of angiogenesis.
  • the control of each of these processes by LPA signaling in physiological and pathophysiological conditions underscores the potential therapeutic usefulness of modulating LPA signaling pathways for the treatment of cancer, especially at the level of the LPA receptors or ATX/lysoPLD.
  • ATX Autotaxin
  • LPA signals through its own GPCRs leading to activation of multiple downstream effector pathways. Such downstream effector pathways play a role in cancer. LPA and its GPCRs are linked to cancer through major oncogenic signaling pathways.
  • LPA contributes to tumorigenesis by increasing motility and invasiveness of cells. LPA has been implicated in the initiation or progression of ovarian cancer. LPA is present at significant concentrations (2-80 mM) in the ascitic fluid of ovarian cancer patients. Ovarian cancer cells constitutively produce increased amounts of LPA as compared to normal ovarian surface epithelial cells, the precursor of ovarian epithelial cancer.
  • Elevated LPA levels are also detected in plasma from patients with early-stage ovarian cancers compared with controls.
  • LPA receptors LPA 2 and LPA-, are also overexpressed in ovarian cancer cells as compared to normal ovarian surface epithelial cells.
  • LPA stimulates Cox-2 expression through transcriptional activation and post-transcriptional enhancement of Cox-2 mRNA in ovarian cancer cells.
  • Prostaglandins produced by Cox-2 have been implicated in a number of human cancers and pharmacological inhibition of Cox-2 activity reduces colon cancer development and decreases the size and number of adenomas in patients with familial adenomatous polyposis.
  • LPA has also been implicated in the initiation or progression of prostate cancer, breast cancer, melanoma, head and neck cancer, bowel cancer (colorectal cancer), thyroid cancer and other cancers (Gardell et al , Trends in Molecular Medicine , vol. 12, no. 2, p 65-75, 2006; Ishii et al , Anna. Rev.
  • LPA receptors mediate both migration of and invasion by pancreatic cancer cell lines: an antagonist of LPAi and LPA 3 (K ⁇ 16425) and LPAi- specific siRNA effectively blocked in vitro migration in response to LPA and peritoneal fluid (ascites) from pancreatic cancer patients; in addition, Ki 16425 blocked the LPA- induced and ascites-induced invasion activity of a highly peritoneal metastatic pancreatic cancer cell line (Yamada et al , J Biol. Chem ., 279, 6595-6605, 2004).
  • LPA 3 was originally cloned from prostate cancer cells, concordant with the ability of LPA to induce autocrine proliferation of prostate cancer cells.
  • LPA has stimulatory roles in cancer progression in many types of cancer.
  • LPA is produced from and induces proliferation of prostate cancer cell lines.
  • LPA induces human colon carcinoma DLD1 cell proliferation, migration, adhesion, and secretion of angiogenic factors through LPAi signaling.
  • LPA enhances cell proliferation and secretion of angiogenic factors.
  • LPA 2 and LPA 3 receptor activation results in proliferation of the cells.
  • the genetic or pharmacological manipulation of LPA metabolism, specific blockade of receptor signaling, and/or inhibition of downstream signal transduction pathways, represent approaches for cancer therapies.
  • concentrations of IL-8 in ovarian cancer correlate with poor initial response to
  • VEGF vascular endothelial growth factor
  • IL-8 is an important modulator of cancer progression, drug resistance, and prognosis in ovarian cancer.
  • a compound of Formula (I) inhibits or reduces IL-8 expression in ovarian cancer cell lines.
  • a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof is used in the treatment of cancer. In one aspect, a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, is used in the treatment of malignant and benign proliferative disease. In one aspect, a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, is used to prevent or reduce proliferation of tumor cells, invasion and metastasis of carcinomas, pleural mesothelioma (Yamada, Cancer Sci., 2008, 99(8), 1603-1610) or peritoneal mesothelioma, cancer pain, bone metastases (Boucharaba et al , J Clin. Invest., 2004, 114(12), 1714-1725;
  • a method of treating cancer in a mammal comprising administering to the mammal a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, and a second therapeutic agent, wherein the second therapeutic agent is an anti cancer agent.
  • cancer refers to an abnormal growth of cells which tend to proliferate in an uncontrolled way and, in some cases, to metastasize (spread).
  • types of cancer include, but is not limited to, solid tumors (such as those of the bladder, bowel, brain, breast, endometrium, heart, kidney, lung, lymphatic tissue (lymphoma), ovary, pancreas or other endocrine organ (thyroid), prostate, skin (melanoma or basal cell cancer) or hematological tumors (such as the leukemias) at any stage of the disease with or without metastases.
  • cancers include, acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, anal cancer, appendix cancer, astrocyto as, atypical teratoid/rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer (osteosarcoma and malignant fibrous histiocytoma), brain stem glioma, brain tumors, brain and spinal cord tumors, breast cancer, bronchial tumors, Burkitt lymphoma, cervical cancer, chronic lymphocytic leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T- Cell lymphoma, embryonal tumors, endometrial cancer, ependymoblastoma,
  • ependymoma esophageal cancer, ewing sarcoma family of tumors, eye cancer, retinoblastoma, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), gastrointestinal stromal cell tumor, germ cell tumor, glioma, hairy cell leukemia, head and neck cancer, hepatocellular (liver) cancer, Hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell tumors (endocrine pancreas), Kaposi sarcoma, kidney cancer, Langerhans cell
  • leukemia Acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, hairy cell leukemia, liver cancer, non-small cell lung cancer, small cell lung cancer, Burkitt lymphoma, cutaneous T-cell lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, lymphoma, Waldenstrom macroglobulinemia, medulloblastoma, medulloepithelioma, melanoma, mesothelioma, mouth cancer, chronic myelogenous leukemia, myeloid leukemia, multiple myeloma, nasopharyngeal cancer, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung cancer, oral cancer, oropharyngeal cancer, osteosarcoma, malignant fibrous histiocytosis, laryngeal cancer, leukemia, A
  • papillomatosis parathyroid cancer, penile cancer, pharyngeal cancer, pineal parenchymal tumors of intermediate differentiation, pineoblastoma and supratentorial primitive neuroectodermal tumors, pituitary tumor, plasma cell neoplasm/multiple myeloma, pleuropulmonary blastoma, primary central nervous system lymphoma, prostate cancer, rectal cancer, renal cell (kidney) cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcoma, Ewing sarcoma family of tumors, sarcoma, kaposi, Sezary syndrome, skin cancer, small cell Lung cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach (gastric) cancer, supratentorial primitive
  • T-cell lymphoma testicular cancer, throat cancer, thymoma and thymic carcinoma, thyroid cancer, urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenstrom macroglobulinemia, Wilms tumor.
  • LPA concentrations are consistently higher in ascites samples than in matched plasma samples.
  • LPA is a contributor to the pathogenesis of respiratory diseases.
  • the respiratory disease is asthma.
  • Proinflammatory effects of LPA include degranulation of mast cells, contraction of smooth-muscle cells and release of cytokines from dendritic cells.
  • Airway smooth muscle cells, epithelial cells and lung fibroblasts all show responses to LPA.
  • LPA induces the secretion of IL-8 from human bronchial epithelial cells.
  • IL-8 is found in increased concentrations in BAL fluids from patients with asthma, chronic obstructive lung disease, pulmonary sarcoidosis and acute respiratory distress syndrome and 11-8 has been shown to exacerbate airway inflammation and airway remodeling of asthmatics.
  • LPAi, LPA 2 and LPA 3 receptors have all been shown to contribute to the LPA-induced IL-8 production.
  • Studies cloning multiple GPCRs that are activated by LPA allowed the demonstration of the presence of mRNA for the LPAi, LPA 2 and LPA 3 in the lung (J.J.A. Contos, et a , Mol. Pharmacol. 58, 1188-1196, 2000).
  • LPA LPA as a mediator of wound repair.
  • asthma is an inflammatory disease where inappropriate airway“repair” processes lead to structural“remodeling” of the airway.
  • the cells of the airway are subject to ongoing injury due to a variety of insults, including allergens, pollutants, other inhaled environmental agents, bacteria and viruses, leading to the chronic inflammation that characterizes asthma.
  • the release of normal repair mediators, including LPA is exaggerated or the actions of the repair mediators are inappropriately prolonged leading to inappropriate airway remodeling.
  • Major structural features of the remodeled airway observed in asthma include a thickened lamina reticularis (the basement membrane-like structure just beneath the airway epithelial cells), increased numbers and activation of myofibroblasts, thickening of the smooth muscle layer, increased numbers of mucus glands and mucus secretions, and alterations in the connective tissue and capillary bed throughout the airway wall.
  • LPA contributes to these structural changes in the airway.
  • LPA is involved in acute airway hyperresponsiveness in asthma.
  • LPA contributes to the long-term structural remodeling and the acute hyperresponsiveness of the asthmatic airway. In one aspect, LPA contributes to the hyper responsiveness that is a primary feature of acute exacerbations of asthma.
  • EGF receptor upregulation is induced by LPA and is also seen in asthmatic airways (M.
  • the fibroblast proliferation and contraction and extracellular matrix secretion stimulated by LPA contributes to the fibroproliferative features of other airway diseases, such as the peribronchiolar fibrosis present in chronic bronchitis, emphysema, and interstitial lung disease.
  • Emphysema is also associated with a mild fibrosis of the alveolar wall, a feature which is believed to represent an attempt to repair alveolar damage.
  • LPA plays a role in the fibrotic interstitial lung diseases and obliterative bronchiolitis, where both collagen and myofibroblasts are increased.
  • LPA is involved in several of the various syndromes that constitute chronic obstructive pulmonary disease.
  • LPA in vivo induces airway hyper-responsiveness, itch-scratch responses, infiltration and activation of eosinophils and neutrophils, vascular remodeling, and nociceptive flexor responses.
  • LPA also induces histamine release from mouse and rat mast cells. In an acute allergic reaction, histamine induces various responses, such as contraction of smooth muscle, plasma exudation, and mucus production. Plasma exudation is important in the airway, because the leakage and subsequent airway-wall edema contribute to the development of airway hyperresponsiveness.
  • Plasma exudation progresses to conjunctival swelling in ocular allergic disorder and nasal blockage in allergic rhinitis (Hashimoto et al., J Pharmacol rici 100, 82 - 87, 2006).
  • plasma exudation induced by LPA is mediated by histamine release from mast cells via one or more LPA receptors.
  • the LPA receptor(s) include LPAi and/or LPA-,.
  • a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, is used in the treatment of various allergic disorders in a mammal.
  • a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof is used in the treatment of respiratory diseases, disorders or conditions in a mammal. In one aspect, a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, is used in the treatment of asthma in a mammal. In one aspect, a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, is used in the treatment of chronic asthma in a mammal.
  • respiratory disease refers to diseases affecting the organs that are involved in breathing, such as the nose, throat, larynx, eustachian tubes, trachea, bronchi, lungs, related muscles ( e.g ., diaphram and intercostal s), and nerves.
  • Respiratory diseases include, but are not limited to, asthma, adult respiratory distress syndrome and allergic (extrinsic) asthma, non-allergic (intrinsic) asthma, acute severe asthma, chronic asthma, clinical asthma, nocturnal asthma, allergen-induced asthma, aspirin-sensitive asthma, exercise-induced asthma, isocapnic hyperventilation, child-onset asthma, adult-onset asthma, cough-variant asthma, occupational asthma, steroid-resistant asthma, seasonal asthma, seasonal allergic rhinitis, perennial allergic rhinitis, chronic obstructive pulmonary disease, including chronic bronchitis or emphysema, pulmonary hypertension, interstitial lung fibrosis and/or airway inflammation and cystic fibrosis, and hypoxia.
  • asthma refers to any disorder of the lungs characterized by variations in pulmonary gas flow associated with airway constriction of whatever cause (intrinsic, extrinsic, or both; allergic or non-allergic).
  • the term asthma may be used with one or more adjectives to indicate cause.
  • chronic obstructive pulmonary disease includes, but is not limited to, chronic bronchitis or emphysema, pulmonary hypertension, interstitial lung fibrosis and/or airway inflammation, and cystic fibrosis.
  • the nervous system is a major locus for LPAi expression; there it is spatially and temporally regulated throughout brain development.
  • Oligodendrocytes the myelinating cells in the central nervous system (CNS)
  • CNS central nervous system
  • LPAi the myelinating cells in the central nervous system
  • Schwann cells the myelinating cells of the peripheral nervous system, also express LPAi, which is involved in regulating Schwann cell survival and morphology.
  • LPA causes neuronal
  • Immortalized CNS neuroblast cell lines from the cerebral cortex also display retraction responses to LPA exposure through Rho activation and actomyosin
  • LPA is associated with post-ischemic neural damage (J.
  • a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof for use in the treatment or prevention of a nervous system disorder in a mammal.
  • the term“nervous system disorder,” as used herein, refers to conditions that alter the structure or function of the brain, spinal cord or peripheral nervous system, including but not limited to Alzheimer’s Disease, cerebral edema, cerebral ischemia, stroke, multiple sclerosis, neuropathies, Parkinson’s Disease, those found after blunt or surgical trauma (including post-surgical cognitive dysfunction and spinal cord or brain stem injury), as well as the neurological aspects of disorders such as degenerative disk disease and sciatica.
  • a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof for use in the treatment or prevention of a CNS disorder in a mammal.
  • CNS disorders include, but are not limited to, multiple sclerosis,
  • Parkinson’s disease Alzheimer’s disease, stroke, cerebral ischemia, retinal ischemia, post-surgical cognitive dysfunction, migraine, peripheral neuropathy/neuropathic pain, spinal cord injury, cerebral edema and head injury.
  • Angiogenesis the formation of new capillary networks from pre-existing vasculature, is normally invoked in wound healing, tissue growth and myocardial angiogenesis after ischemic injury.
  • Peptide growth factors e.g. vascular endothelial growth factor (VEGF)
  • VEGF vascular endothelial growth factor
  • lysophospholipids control coordinated proliferation, migration, adhesion, differentiation and assembly of vascular endothelial cells (VECs) and surrounding vascular smooth- muscle cells (VSMCs).
  • VECs vascular endothelial cells
  • VSMCs vascular smooth- muscle cells
  • dysregulation of the processes mediating angiogenesis leads to atherosclerosis, hypertension, tumor growth, rheumatoid arthritis and diabetic retinopathy (Osborne, N. and Stainier, D.Y. Annu. Rev. Physiol. 65, 23-43, 2003).
  • Downstream signaling pathways evoked by lysophospholipid receptors include Rac-dependent lamellipodia formation (e.g. LPAi) and Rho-dependent stress-fiber formation (e.g. LPAi), which is important in cell migration and adhesion.
  • Dysfunction of the vascular endothelium can shift the balance from vasodilatation to vasoconstriction and lead to hypertension and vascular remodeling, which are risk factors for atherosclerosis (Maguire, J.J. et ah, Trends Pharmacol. Sci. 26, 448-454, 2005).
  • LPA contributes to both the early phase (barrier dysfunction and monocyte adhesion of the endothelium) and the late phase (platelet activation and intra-arterial thrombus formation) of atherosclerosis, in addition to its overall progression.
  • LPAi and LPAi cognate GPCRs expressed on platelets
  • LPA can also be a mitogen and motogen to VSMCs and an activator of endothelial cells and macrophages.
  • mammals with cardiovascular disease benefit from LPA receptor antagonists that prevent thrombus and neointima plaque formation.
  • a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof is used to treat or prevent cardiovascular disease in mammal.
  • cardiovascular disease refers to diseases affecting the heart or blood vessels or both, including but not limited to: arrhythmia (atrial or ventricular or both); atherosclerosis and its sequelae; angina; cardiac rhythm disturbances; myocardial ischemia; myocardial infarction; cardiac or vascular aneurysm; vasculitis, stroke; peripheral obstructive arteriopathy of a limb, an organ, or a tissue; reperfusion injury following ischemia of the brain, heart or other organ or tissue; endotoxic, surgical, or traumatic shock; hypertension, valvular heart disease, heart failure, abnormal blood pressure; shock; vasoconstriction (including that associated with migraines); vascular abnormality, inflammation, insufficiency limited to a single organ or tissue.
  • provided herein are methods for preventing or treating
  • vasoconstriction atherosclerosis and its sequelae myocardial ischemia, myocardial infarction, aortic aneurysm, vasculitis and stroke comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, or pharmaceutical composition or medicament which includes a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof.
  • provided herein are methods for reducing cardiac reperfusion injury following myocardial ischemia and/or endotoxic shock comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof.
  • provided herein are methods for reducing the constriction of blood vessels in a mammal comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof.
  • provided herein are methods for lowering or preventing an increase in blood pressure of a mammal comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof.
  • LPA has been shown to regulate immunological responses by modulating activities/functions of immune cells such as T-/B-lymphocytes and macrophages.
  • LPA activates IL-2 production/cell proliferation through LPAi (Gardell et al, TRENDS in Molecular Medicine Vol.l2 No.2 February 2006).
  • LPA- induced inflammatory response genes is mediated by LPAi and LPA 3 ( Biochem Biophys Res Commun. 363(4): 1001-8, 2007).
  • LPA modulates the chemotaxis of inflammatory cells (Biochem Biophys Res Commun., 1993, 15; 193(2), 497).
  • the proliferation and cytokine-secreting activity in response to LPA of immune cells ( ./.
  • LPA platelet aggregation activity in response to LPA
  • acceleration of migration activity in monocytes activation of NF-kB in fibroblast
  • enhancement of fibronectin-binding to the cell surface and the like are known.
  • LPA is associated with various inflammatory/immune diseases.
  • a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof is used to treat or prevent inflammation in a mammal.
  • antagonists of LPAi and/or LPA 3 find use in the treatment or prevention of
  • the antagonist of LPAi is a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof.
  • inflammatory/immune disorders include psoriasis, rheumatoid arthritis, vasculitis, inflammatory bowel disease, dermatitis, osteoarthritis, asthma, inflammatory muscle disease, allergic rhinitis, vaginitis, interstitial cystitis, scleroderma, eczema, allogeneic or xenogeneic transplantation (organ, bone marrow, stem cells and other cells and tissues) graft rejection, graft-versus-host disease, lupus erythematosus, inflammatory disease, type I diabetes, pulmonary fibrosis, dermatomyositis, Sjogren's syndrome, thyroiditis ( e.g ., Hashimoto's and autoimmune thyroiditis), myasthenia gravis, autoimmune hemolytic anemia, multiple sclerosis, cystic fibrosis, chronic relapsing hepatitis, primary biliary cirrhosis, allergic conjunctivit
  • LP A-dependent or LPA-mediated diseases or conditions are methods for treating, preventing, reversing, halting or slowing the progression of LP A-dependent or LPA-mediated diseases or conditions once it becomes clinically evident, or treating the symptoms associated with or related to LP A-dependent or LPA-mediated diseases or conditions, by administering to the mammal a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof.
  • the subject already has a LP A-dependent or LPA- mediated disease or condition at the time of administration, or is at risk of developing a LP A-dependent or LPA-mediated disease or condition.
  • the activity of LPAi in a mammal is directly or indirectly modulated by the administration of (at least once) a therapeutically effective amount of at least one compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof.
  • modulation includes, but is not limited to, reducing and/or inhibiting the activity of LPAi.
  • the activity of LPA in a mammal is directly or indirectly modulated, including reducing and/or inhibiting, by the administration of (at least once) a therapeutically effective amount of at least one compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof.
  • modulation includes, but is not limited to, reducing and/or inhibiting the amount and/or activity of a LPA receptor.
  • the LPA receptor is LPAi.
  • LPA has a contracting action on bladder smooth muscle cell isolated from bladder, and promotes growth of prostate-derived epithelial cell (J.
  • LPA contracts the urinary tract and prostate in vitro and increases intraurethral pressure in vivo (WO 02/062389).
  • are methods for preventing or treating eosinophil and/or basophil and/or dendritic cell and/or neutrophil and/or monocyte and/or T-cell recruitment comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof.
  • cystitis In certain aspects, are methods for the treatment of cystitis, including,
  • interstitial cystitis comprising administering at least once to the mammal a therapeutically effective amount of at least one compound of Formula (I), or a
  • methods described herein include the diagnosis or determination of whether or not a patient is suffering from a LPA-dependent or LPA-mediated disease or condition by administering to the subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, and determining whether or not the patient responds to the treatment.
  • LPA-dependent or LPA-mediated conditions or diseases including, but not limited to, lung fibrosis, kidney fibrosis, liver fibrosis, scarring, asthma, rhinitis, chronic obstructive pulmonary disease, pulmonary hypertension, interstitial lung fibrosis, arthritis, allergy, psoriasis, inflammatory bowel disease, adult respiratory distress syndrome, myocardial infarction, aneurysm, stroke, cancer, pain, proliferative disorders and inflammatory conditions.
  • LPA-dependent conditions or diseases include those wherein an absolute or relative excess of LPA is present and/or observed.
  • the LPA-dependent or LPA-mediated diseases or conditions include, but are not limited to, organ fibrosis, asthma, allergic disorders, chronic obstructive pulmonary disease, pulmonary hypertension, lung or pleural fibrosis, peritoneal fibrosis, arthritis, allergy, cancer, cardiovascular disease, ult respiratory distress syndrome, myocardial infarction, aneurysm, stroke, and cancer.
  • a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof is used to improve the corneal sensitivity decrease caused by corneal operations such as laser-assisted in situ keratomileusis (LASIK) or cataract operation, corneal sensitivity decrease caused by corneal degeneration, and dry eye symptom caused thereby.
  • corneal operations such as laser-assisted in situ keratomileusis (LASIK) or cataract operation
  • corneal sensitivity decrease caused by corneal degeneration corneal sensitivity decrease caused by corneal degeneration
  • dry eye symptom caused thereby.
  • a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof in the treatment or prevention of ocular inflammation and allergic conjunctivitis, vernal keratoconjunctivitis, and papillary conjunctivitis in a mammal comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof.
  • a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof in the treatment or prevention of Sjogren disease or inflammatory disease with dry eyes in a mammal comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof.
  • LPA and LPA receptors are involved in the
  • LPA receptors e.g. LPAi, LPA 3
  • LPAi, LPA 3 contribute to the pathogenesis of rheumatoid arthritis (Zhao et al, Mol. Pharmacol ., 2008, 73(2), 587-600).
  • a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof in the treatment or prevention of rheumatoid arthritis in a mammal comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof.
  • LPA receptors contribute to adipogenesis.
  • LPAi LPA receptors
  • presented herein is the use of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, in the promotion of adipose tissue formation in a mammal comprising administering at least once to the mammal an effective amount of at least one compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof.
  • Chinese hamster ovary cells overexpressing human LPAi were plated overnight (15,000 cells/well) in poly-D-lysine coated 384-well microplates (Greiner bio-one,
  • Test compounds solubilized in DMSO were transferred to 384 well non binding surface plates (Corning, Cat# 3575) using the Labcyte Echo acoustic dispense and diluted with assay buffer [IX HBSS with calcium/magnesium (Gibco Cat# 14025- 092), 20 mM HEPES (Gibco Cat# 15630-080) and 0.1% fatty acid free BSA (Sigma Cat# A9205)] to a final concentration of 0.5% DMSO. Diluted compounds were added to the cells by FDSS6000 (Hamamatsu) at final concentrations ranging from 0.08 nM to 5 mM.
  • IC50 value was defined as the concentration of test compound which inhibited 50% of the calcium flux induced by LPA alone. IC50 values were determined by fitting data to a 4-parameter logistic equation (GraphPad Prism, San Diego CA). b. In Vivo Assays
  • mice Compound is dosed orally p.o. 2 hours to CD-l female mice prior to the LPA challenge.
  • the mice are then dosed via tail vein (IV) with 0.15 mL of LPA in 0. l%BSA/ PBS (2 pg/pL). Exactly 2 minutes following the LPA challenge, the mice are euthanized by decapitation and the trunk blood is collected. These samples are collectively centrifuged and individual 75 pL samples are frozen at -20°C until the time of the histamine assay.
  • Plasma histamine analysis was run by standard EIA (Enzyme Immunoassay) methods. Plasma samples were thawed and diluted 1 :30 in 0.1% BSA in PBS. The EIA protocol for histamine analysis as outlined by the manufacturer was followed (Histamine EIA, Oxford Biomedical Research, EA#3 l).
  • LPA l-oleoyl-2-hydroxy-sn- glycero-3 -phosphate (sodium salt), 857130P, Avanti Polar Lipids) is prepared in
  • a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof.
  • the pharmaceutical composition also contains at least one pharmaceutically acceptable inactive ingredient.
  • a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable inactive ingredient.
  • the pharmaceutical composition is formulated for intravenous injection, subcutaneous injection, oral administration, inhalation, nasal administration, topical administration, ophthalmic administration or otic administration.
  • the pharmaceutical composition is a tablet, a pill, a capsule, a liquid, an inhalant, a nasal spray solution, a suppository, a suspension, a gel, a colloid, a dispersion, a suspension, a solution, an emulsion, an ointment, a lotion, an eye drop or an ear drop.
  • the pharmaceutical composition further comprises one or more additional therapeutically active agents selected from: corticosteroids (e.g ., dexamethasone or fluticasone), immunosuppresants (e.g., tacrolimus & pimecrolimus), analgesics, anti-cancer agent, anti-inflammatories, chemokine receptor antagonists, bronchodilators, leukotriene receptor antagonists (e.g, montelukast or zafirlukast), leukotriene formation inhibitors, monoacylglycerol kinase inhibitors, phospholipase Ai inhibitors, phospholipase A 2 inhibitors, and lysophospholipase D (lysoPLD) inhibitors, autotaxin inhibitors, decongestants, antihistamines (e.g, loratidine), mucolytics, anticholinergics, antitussives, expectorants, anti-infectives (e.
  • the pharmaceutical composition further comprises one or more additional anti-fibrotic agents selected from pirfenidone, nintedanib, thalidomide, carlumab, FG-3019, fresolimumab, interferon alpha, lecithinized superoxide dismutase, pumpuzumab, tanzisertib, tralokinumab, hu3G9, AM- 152, IFN-gamma-lb, IW-001, PRM- 151, PXS-25, pentoxifylline/N-acetyl-cysteine, pentoxifylline/vitamin E, salbutamol sulfate, [Sar9,Met(02)l l]-Substance P, pentoxifylline, mercaptamine bitartrate, obeticholic acid, aramchol, GFT-505, eicosapentaenoic acid ethyl ester, metformin, metre
  • a method comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, to a human with a LPA-dependent or LPA-mediated disease or condition.
  • the human is already being administered one or more additional therapeutically active agents other than a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof.
  • the method further comprises administering one or more additional therapeutically active agents other than a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof.
  • the one or more additional therapeutically active agents other than a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof are selected from: corticosteroids (e.g,. dexamethasone or fluticasone), immunosuppresants (e.g., tacrolimus & pimecrolimus), analgesics, anti-cancer agent, anti-inflammatories, chemokine receptor antagonists, bronchodilators, leukotriene receptor antagonists (e.g, montelukast or zafirlukast), leukotriene formation inhibitors, monoacylglycerol kinase inhibitors, phospholipase Ai inhibitors, phospholipase A 2 inhibitors, and lysophospholipase D (lysoPLD) inhibitors, autotaxin inhibitors, decongestants, antihistamines (e.g, loratidine), mucolytics, anticholinergics,
  • TACE inhibitors drugs that modulate activity of Th2 cytokines IL-4 & IL-5 (e.g, blocking monoclonal antibodies & soluble receptors), PPARy agonists (e.g, rosiglitazone and pioglitazone), 5 -lipoxygenase inhibitors (e.g, zileuton).
  • Th2 cytokines IL-4 & IL-5 e.g, blocking monoclonal antibodies & soluble receptors
  • PPARy agonists e.g, rosiglitazone and pioglitazone
  • 5 -lipoxygenase inhibitors e.g, zileuton
  • the one or more additional therapeutically active agents other than a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof are other anti-fibrotic agents selected from pirfenidone, nintedanib, thalidomide, carlumab, FG-3019, fresolimumab, interferon alpha, lecithinized superoxide dismutase, pumpuzumab, tanzisertib, tralokinumab, hu3G9, AM- 152, IFN-gamma-lb, IW-001, PRM- 151, PXS-25, pentoxifylline/N-acetyl-cysteine, pentoxifylline/vitamin E, salbutamol sulfate, [Sar9,Met(02)l l]-Substance P, pentoxifylline, mercaptamine bitartrate, obeticholic acid, aramchol, GFT-505,
  • the one or more additional therapeutically active agents other than a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof are selected from ACE inhibitors, ramipril, All antagonists, irbesartan, anti- arrythmics, dronedarone, PPARa activators, PPARy activators, pioglitazone,
  • rosiglitazone prostanoids, endothelin receptor antagonists, elastase inhibitors, calcium antagonists, beta blockers, diuretics, aldosterone receptor antagonists, eplerenone, renin inhibitors, rho kinase inhibitors, soluble guanylate cyclase (sGC) activators, sGC sensitizers, PDE inhibitors, PDE5 inhibitors, NO donors, digitalis drugs, ACE/NEP inhibitors, statins, bile acid reuptake inhibitors, PDGF antagonists, vasopressin antagonists, aquaretics, NHE1 inhibitors, Factor Xa antagonists, Factor XHIa antagonists, anticoagulants, anti-thrombotics, platelet inhibitors, profibroltics, thrombin-activatable fibrinolysis inhibitors (TAFI), PAI-l inhibitors, coumarins, heparins, thromboxane antagonists, serotonin antagonists,
  • the one or more additional therapeutically active agents other than a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof are selected from Gremlin-l mAb, PA1-1 mAb, Promedior (PRM-151;
  • FGF21 recombinant human Pentraxin-2
  • TGF antagonists anb ⁇ & anb pan antagonists
  • FAR inhibitors TG2 inhibitors, LOXL2 inhibitors, NOX4 inhibitors, MGAT2 inhibitors, GPR120 agonists.
  • compositions described herein are administrable to a subject in a variety of ways by multiple administration routes, including but not limited to, oral, parenteral (e.g ., intravenous, subcutaneous, intramuscular), intranasal, buccal, topical or transdermal administration routes.
  • the pharmaceutical formulations described herein include, but are not limited to, aqueous liquid dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid dosage forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate and controlled release formulations.
  • the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof is administered orally. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, is administered topically. In such embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, is formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, shampoos, scrubs, rubs, smears, medicated sticks, medicated bandages, balms, creams or ointments. Such pharmaceutical compounds can contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives. In one aspect, the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, is administered topically to the skin.
  • the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof is administered by inhalation.
  • the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof is administered by inhalation that directly targets the pulmonary system.
  • the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof is formulated for intranasal administration.
  • Such formulations include nasal sprays, nasal mists, and the like.
  • the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof is formulated as eye drops.
  • the LPA is selected from LPAi, LPA 2 , LPA-,, LPA 4 , LPA 5 and LPA 6.
  • the LPA receptor is LPAi.
  • the disease or condition is any of the diseases or conditions specified herein.
  • any of the aforementioned aspects are further embodiments in which: (a) the effective amount of the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, is systemically administered to the mammal; and/or (b) the effective amount of the compound is administered orally to the mammal; and/or (c) the effective amount of the compound is intravenously administered to the mammal; and/or (d) the effective amount of the compound is administered by inhalation; and/or (e) the effective amount of the compound is administered by nasal administration; or and/or (f) the effective amount of the compound is administered by injection to the mammal; and/or (g) the effective amount of the compound is administered topically to the mammal; and/or (h) the effective amount of the compound is administered by ophthalmic administration; and/or (i) the effective amount of the compound is administered rectally to the mammal; and/or (j) the effective amount is administered non-systemically or locally to the mammal.
  • any of the aforementioned aspects are further embodiments comprising single administrations of the effective amount of the compound, including further embodiments in which (i) the compound is administered once; (ii) the compound is administered to the mammal multiple times over the span of one day; (iii) continually; or (iv) continuously.
  • any of the aforementioned aspects are further embodiments comprising multiple administrations of the effective amount of the compound, including further embodiments in which (i) the compound is administered continuously or intermittently: as in a a single dose; (ii) the time between multiple administrations is every 6 hours; (iii) the compound is administered to the mammal every 8 hours; (iv) the compound is administered to the mammal every 12 hours; (v) the compound is administered to the mammal every 24 hours.
  • the method comprises a drug holiday, wherein the administration of the compound is temporarily suspended or the dose of the compound being administered is temporarily reduced; at the end of the drug holiday, dosing of the compound is resumed.
  • the length of the drug holiday varies from 2 days to 1 year.
  • Also provided is a method of inhibiting the physiological activity of LPA in a mammal comprising administering a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof to the mammal in need thereof.
  • a medicament for treating a LPA-dependent or LPA- mediated disease or condition in a mammal comprising a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof.
  • a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of a LPA-dependent or LPA-mediated disease or condition.
  • a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof in the treatment or prevention of a LPA-dependent or LPA-mediated disease or condition.
  • a method for treating or preventing a LPA-dependent or LPA- mediated disease or condition in a mammal comprising administering a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof.
  • LPA-dependent or LPA-mediated diseases or conditions include, but are not limited to, fibrosis of organs or tissues, scarring, liver diseases, dermatological conditions, cancer, cardiovascular disease, respiratory diseases or conditions,
  • inflammatory disease gastrointestinal tract disease, renal disease, urinary tract-associated disease, inflammatory disease of lower urinary tract, dysuria, frequent urination, pancreas disease, arterial obstruction, cerebral infarction, cerebral hemorrhage, pain, peripheral neuropathy, and fibromyalgia.
  • the LPA-dependent or LPA-mediated disease or condition is a respiratory disease or condition.
  • the respiratory disease or condition is asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, pulmonary arterial hypertension or acute respiratory distress syndrome.
  • COPD chronic obstructive pulmonary disease
  • pulmonary fibrosis pulmonary arterial hypertension or acute respiratory distress syndrome.
  • the LPA-dependent or LPA-mediated disease or condition is selected from idiopathic pulmonary fibrosis; other diffuse parenchymal lung diseases of different etiologies including iatrogenic drug-induced fibrosis, occupational and/or environmental induced fibrosis, granulomatous diseases (sarcoidosis, hypersensitivity pneumonia), collagen vascular disease, alveolar proteinosis, langerhans cell
  • granulomatosis lymphangioleiomyomatosis, inherited diseases (Hermansky-Pudlak Syndrome, tuberous sclerosis, neurofibromatosis, metabolic storage disorders, familial interstitial lung disease); radiation induced fibrosis; chronic obstructive pulmonary disease (COPD); scleroderma; bleomycin induced pulmonary fibrosis; chronic asthma; silicosis; asbestos induced pulmonary fibrosis; acute respiratory distress syndrome (ARDS); kidney fibrosis; tubulointerstitium fibrosis; glomerular nephritis; focal segmental glomerular sclerosis; IgA nephropathy; hypertension; Alport; gut fibrosis; liver fibrosis; cirrhosis; alcohol induced liver fibrosis; toxic/drug induced liver fibrosis;
  • COPD chronic obstructive pulmonary disease
  • COPD chronic obstructive pulmonary disease
  • COPD chronic obstructive
  • hemochromatosis nonalcoholic steatohepatitis (NASH); biliary duct injury; primary biliary cirrhosis; infection induced liver fibrosis; viral induced liver fibrosis; and autoimmune hepatitis; corneal scarring; hypertrophic scarring; Duputren disease, keloids, cutaneous fibrosis; cutaneous scleroderma; spinal cord injury/fibrosis; myelofibrosis; vascular restenosis; atherosclerosis; arteriosclerosis; Wegener's granulomatosis;
  • Peyronie's disease chronic lymphocytic leukemia, tumor metastasis, transplant organ rejection, endometriosis, neonatal respiratory distress syndrome and neuropathic pain.
  • the LPA-dependent or LPA-mediated disease or condition is described herein.
  • a method for the treatment or prevention of organ fibrosis in a mammal comprising administering a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof to a mammal in need thereof.
  • the organ fibrosis comprises lung fibrosis, renal fibrosis, or hepatic fibrosis.
  • a method of improving lung function in a mammal comprising administering a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof to the mammal in need thereof.
  • the mammal has been diagnosed as having lung fibrosis.
  • compounds disclosed herein are used to treat idiopathic pulmonary fibrosis (usual interstitial pneumonia) in a mammal.
  • compounds disclosed herein are used to treat diffuse parenchymal interstitial lung diseases in mammal: iatrogenic drug induced,
  • compounds disclosed herein are used to treat post- transplant fibrosis associated with chronic rejection in a mammal: Bronchiolitis obliterans for lung transplant.
  • compounds disclosed herein are used to treat cutaneous fibrosis in a mammal: cutaneous scleroderma, Dupuytren disease, keloids.
  • compounds disclosed herein are used to treat hepatic fibrosis with or without cirrhosis in a mammal: toxic/drug induced (hemochromatosis), alcoholic liver disease, viral hepatitis (hepatitis B virus, hepatitis C virus, HCV), nonalcoholic liver disease (NAFLD, NASH), metabolic and auto-immune disease.
  • compounds disclosed herein are used to treat renal fibrosis in a mammal: tubulointerstitium fibrosis, glomerular sclerosis.
  • any of the aforementioned aspects involving the treatment of LPA dependent diseases or conditions are further embodiments comprising administering at least one additional agent in addition to the administration of a compound having the structure of Formula (I), or a pharmaceutically acceptable salt or solvate thereof.
  • each agent is administered in any order, including simultaneously.
  • the mammal is a human.
  • compounds provided herein are administered to a human.
  • compounds provided herein are orally administered.
  • compounds provided herein are used as antagonists of at least one LPA receptor. In some embodiments, compounds provided herein are used for inhibiting the activity of at least one LPA receptor or for the treatment of a disease or condition that would benefit from inhibition of the activity of at least one LPA receptor.
  • the LPA receptor is LPAi.
  • compounds provided herein are used for the formulation of a medicament for the inhibition of LPAi activity.
  • Articles of manufacture which include packaging material, a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, within the packaging material, and a label that indicates that the compound or composition, or pharmaceutically acceptable salt, tautomers, pharmaceutically acceptable N-oxide, pharmaceutically active metabolite, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof, is used for inhibiting the activity of at least one LPA receptor, or for the treatment, prevention or amelioration of one or more symptoms of a disease or condition that would benefit from inhibition of the activity of at least one LPA receptor, are provided.
  • the compounds of the present invention can be prepared in a number of ways known to one skilled in the art of organic synthesis.
  • the compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or by variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below.
  • the reactions are performed in a solvent or solvent mixture appropriate to the reagents and materials employed and suitable for the transformations being effected. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule should be consistent with the transformations proposed. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention.
  • the compounds of Formula (I) may be prepared by the exemplary processes described in the following schemes and working examples, as well as relevant published literature procedures that are used by one skilled in the art. Exemplary reagents and procedures for these reactions appear herein after and in the working examples.
  • Scheme 1 describes the synthesis of amino-pyridyl/pyrimidinyl methyl triazole- aryl oxy cyclohexyl acids 16.
  • a dihalo (preferably dibromo) phenyl or azine e.g.
  • pyridine) derivative 1 is coupled with an appropriately protected (e.g. as a
  • trimethyl silyl azide is a viable replacement reagent (Qian, Y. et al, ./. Med. Chem ., 2012, 55 , 7920-7939) that can be used under either thermal or transition-metal catalyzed conditions (Boren, B.C. et. al., J Am. Chem. Soc., 2008, 130, 8923-8930).
  • the desired triazole regioisomer 18 is obtained as the major product of the 1,3- dipolar cycloaddition reaction, and the trimethylsilyl group is subsequently removed under standard desilylation conditions (e.g. Bu 4 NF, as in Qian, Y. et al, ./. Med. Chem ., 2012, 55, 7920-7939).
  • Scheme 2 describes an alternative synthetic route to the amino- pyridyl/pyrimidinyl methyl triazole-aryl oxy cyclohexyl acids 16.
  • a dihalo (preferably dibromo) phenyl or azine (e.g. pyridine) derivative 1 is coupled with propargyl alcohol under Sonogashira conditions (Alper, P. et al, WO 2008097428) to give the amino- pyridyl/pyrimidinyl methyl triazole-aryl oxy cyclohexyl acids 16.
  • a dihalo (preferably dibromo) phenyl or azine (e.g. pyridine) derivative 1 is coupled with propargyl alcohol under Sonogashira conditions (Alper, P. et al, WO 2008097428) to give the
  • Scheme 3 describes a synthetic route to the amino- pyridyl/pyrimidinyl methyl triazole-aryl oxy cyclohexyl acids 16.
  • Reacting of the amino pyridine/pyrimidine 14 with the bromide 11 and base (such as NaH, etc.,) afforded the amino-pyridyl/pyrimidinyl methyl triazole-aryl oxy cyclohexyl ester 15.
  • Subsequent ester deprotection of compound 15 gave the desired amino-pyridyl/pyrimidinyl methyl triazole-aryl oxy cyclohexyl acids 16.
  • Scheme 4 describes a synthetic route to the amino-triazinyl methyl triazole- aryl oxy cyclohexyl acids 32 and 34.
  • Reacting of a dihalotriazine 29 with the amine 13 and base affords the amino-halotriazinyl methyl triazole-aryloxy cyclohexyl ester 30.
  • Subsequent dehalogenation of the halotriazine compound 30 followed by ester deprotection provides the desired acids 32.
  • displacement of halogen of halotriazine 30 with R 4 OH in the presence of base gives the alkoxytriazine compound 33, which is subjected to ester deprotection to afford acids 34.
  • Scheme 5 describes the synthesis of amino-azine triazole-pyrimidinyl oxycyclohexyl acids 40. Reaction of 5-hydroxy-2-halo-pyrimidine 35 with a 3 -hydroxy cycloalkyl ester 8 under Mitsunobu reaction conditions furnishes the corresponding pyrimidinyl cyclohexyl ether ester 36. Halo-pyrimidine 36 is then subjected to a
  • Scheme 6 describes an alternative synthetic route to triazole azine acids 16.
  • the halo-tri azole 19 is deprotected to give the alcohol, which is then converted to the corresponding bromide 41 (with a brominating agent such as PBr 3 or CBn/Ph P), and subsequently to the amine 42 (via a 2-step sequence as in Scheme 1 with NaN 3 displacement of the bromide, followed by a Staudinger reduction of the azide
  • Scheme 7 describes the synthesis of triazole-ethyl-azine cyclohexyl acids 51.
  • the triazole methanol intermediate 10 is oxidized to the corresponding aldehyde (e.g. Dess- Martin periodinane or Swem oxidation), which is then subjected to an olefmation reaction (e.g. Wittig or Peterson olefmation reaction) which provides the terminal olefin 45.
  • aldehyde e.g. Dess- Martin periodinane or Swem oxidation
  • an olefmation reaction e.g. Wittig or Peterson olefmation reaction
  • bromide 47 CBr 4 /Ph 3 P
  • amine 49 Displacement of bromide 47 with NaN 3 (or other azide equivalent reagents) gives azide 48 which undergoes reduction (e.g. Staudinger reduction with Ph 3 P/water) to afford amine 49.
  • Amine 49 is then reacted with halo-pyridine/pyrimidine 14 in the presence of an appropriate base or via Pd catalyzed amination to give the triazole amino pyridine/pyrimidine 50, which then undergoes ester deprotection to give the desired triazole-ethyl-aminoazine-aryloxy cyclohexyl acids 51.
  • Scheme 8 describes the synthesis of triazole amino-azine acids 56.
  • Cyclohexyl ether triazole-alcohol 10 undergoes oxidation to the carboxylic acid 52 (e.g. directly to the acid with pyridinium di chromate or via a 2-step procedure via the aldehyde [Swem oxidation or Dess-Martin periodinane followed by NaClCh oxidation to the acid, e.g. Lindgren, B. O., Acta Chem. Scand. 1973, 27, 888]).
  • Curtius rearrangement of 52 in the presence of t-butanol provides the triazole NH-Boc-carbamate 53.
  • Triazole NH-Boc carbamate 53 under acidic conditions provides the triazole amine 54.
  • the triazole-amine 54 then undergoes a transition metal-catalyzed cross-coupling reaction with a halo-pyridine/pyrimidine 14 to give the triazole amino-azine 55, which then undergoes ester deprotection to give the desired triazole-ethyl-aminoazine-aryloxy cyclohexyl acids 56.
  • Scheme 9 describes the synthesis of triazole oxy-azine cyclohexyl acids 59.
  • the cyclohexyl ester triazole-alcohol 10 is deprotected to give the hydroxymethyl triazole- cyclohexyl acid 57.
  • Base-mediated S N AT reaction of triazole alcohol 57 with an appropriate azine halide 58 provides the desired triazole oxy-azine cyclohexyl acids 59.
  • the cyclohexyl ester triazole-alcohol 10 is reacted with an azine halide 58 under either transition metal-catalysis conditions (e.g.
  • Scheme 10 describes an alternate syntheses of triazole oxy-azine cyclohexyl acids 59.
  • the cyclohexyl ester-triazole bromide 11 is reacted with an appropriate hydroxy- azine 61 under basic conditions suitable for bromide displacement or silver-mediated (e.g. Ag?CO,) conditions to afford triazole oxy-azine cyclohexyl ester 60, which upon ester deprotection provides the desired triazole oxy-azine cyclohexyl acids 59.
  • the triazole oxyazine cyclohexyl ester 60 can also be obtained by the reaction of triazole alcohol 10 and an appropriate hydroxy-azine 61 under Mitsunobu reaction conditions.
  • Scheme 11 describes the synthesis of triazole oxy-azine cyclohexyl tetrazole 64.
  • Reaction of triazole oxy-azine cyclohexyl acid 59 with oxalyl chloride/catalytic DMF provides the corresponding acid chloride, which upon treatment with ammonia gives the cyclohexyl amide 62.
  • Dehydration of cyclohexyl amide 62 with the Burgess reagent (Talibi, P. et al., e -EROS Encyclopedia of Reagents for Organic Synthesis , published online 15 Sept.
  • Scheme 12 describes the synthesis of cyclohexyl acids 66.
  • the cyclohexyl ester triazole-alcohol 10 is converted to the corresponding mesylate, which is then subjected to a cobalt/nickel-catalyzed cross electrophile coupling which yields the
  • diheteroarylmethanes 65 (Weix, D. J., Chem. Sci., 2015, 6, 1115). Deprotection of 65 furnishes the desired cyclohexyl acids 66.
  • Microwave reactions were carried out using a 400W Biotage Initiator instrument in microwave reaction vessels under microwave (2.5 GHz) irradiation.
  • HPLC refers to a Shimadzu high performance liquid chromatography instrument with one of following methods:
  • HPLC-l Sunfire C18 column (4.6 x 150 mm) 3.5 pm, gradient from 10 to 100% B:A for 12 min, then 3 min hold at 100% B.
  • Mobile phase A 0.05% TFA in water:CH 3 CN (95:5)
  • TFA Buffer pH 2.5; Flow rate: 1 mL/ min; Wavelength: 254 nm, 220 nm.
  • HPLC-3 Chiralpak AD-H, 4.6 x 250 mm, 5 pm.
  • HPLC-5 Waters Acquity UPLC BEH C 18, 2.1 x 50 mm, l.7-pm particles;
  • TMSCH 2 N 3 (7.85 g, 60.8 mmol) was heated at 90 °C under Ar for 15 h, then was cooled to RT. Volatiles were removed in vacuo and the residue was dissolved in THF (20 mL). To the mixture was added TBAF (20.3 mL of a 1 M solution in THF, 20.3 mmol) at 0 °C. After stirring for 10 min, the reaction was complete as determined by analytical HPLC. Volatiles were removed in vacuo and the residue was chromatographed (S1O2; continuous gradient from 0% to 100% EtOAc in hexanes over 20 min) to give the title compound (2.1 g, 29 % yield) as a white solid.
  • the crude product was purified by preparative LC/MS (Column: Waters XBridge C18, 19 x 200 mm, 5-pm particles; Guard Column: Waters XBridge C18, 19 x 10 mm, 5-pm particles; Mobile Phase A: 5:95 MeCN:H 2 0 with 0.1% TFA; Mobile Phase B: 95:5 MeCN:H 2 0 with 0.1% TFA; Gradient: 50-90% B over 20 min, then a 5-min hold at 100% B; Flow: 20 mL/min) to give the title compound. (130 mg;

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des composés de formule (I) : formule (I) ou un stéréoisomère, un tautomère ou un sel pharmaceutiquement acceptable ou un solvate de ceux-ci ; dans la formule, toutes les variables sont telles que définies dans la description. Ces composés sont des inhibiteurs sélectifs du récepteur de LPA.
EP18830681.5A 2017-12-19 2018-12-18 Azines triazoles d'acide cyclohexyle utilisées en tant qu'antagonistes de lpa Active EP3728223B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762607383P 2017-12-19 2017-12-19
US201862771214P 2018-11-26 2018-11-26
PCT/US2018/066121 WO2019126093A1 (fr) 2017-12-19 2018-12-18 Azines triazoles d'acide cyclohexyle utilisées en tant qu'antagonistes de lpa

Publications (2)

Publication Number Publication Date
EP3728223A1 true EP3728223A1 (fr) 2020-10-28
EP3728223B1 EP3728223B1 (fr) 2022-12-28

Family

ID=65003580

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18830681.5A Active EP3728223B1 (fr) 2017-12-19 2018-12-18 Azines triazoles d'acide cyclohexyle utilisées en tant qu'antagonistes de lpa

Country Status (14)

Country Link
US (1) US11267800B2 (fr)
EP (1) EP3728223B1 (fr)
JP (1) JP7208240B2 (fr)
KR (1) KR20200100719A (fr)
CN (1) CN112055711B (fr)
AU (1) AU2018392324A1 (fr)
BR (1) BR112020011965A2 (fr)
CA (1) CA3085561A1 (fr)
ES (1) ES2936517T3 (fr)
IL (1) IL275346A (fr)
MX (1) MX2020005323A (fr)
SG (1) SG11202005698XA (fr)
TW (1) TW202017918A (fr)
WO (1) WO2019126093A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
KR20200100723A (ko) * 2017-12-19 2020-08-26 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 피라졸 아진
CN111434653A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 三氮唑类化合物及其制备方法与用途
EA202192840A1 (ru) * 2019-04-16 2022-01-26 Бристол-Маерс Сквибб Компани Способ получения соединений карбамоилоксиметилтриазолциклогексиловой кислоты
US11548871B2 (en) 2019-11-15 2023-01-10 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
WO2021215484A1 (fr) 2020-04-21 2021-10-28 東レ株式会社 Procédé de récupération de sel de métal rare
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
WO2021247215A1 (fr) 2020-06-03 2021-12-09 Gilead Sciences, Inc. Antagonistes du récepteur lpa et leurs utilisations
CN112142716B (zh) * 2020-10-29 2021-08-31 山东新时代药业有限公司 一种5元杂芳基取代的吡嗪衍生物及其应用
CN114456159A (zh) * 2020-11-10 2022-05-10 武汉人福创新药物研发中心有限公司 氮取代杂环噻吩类化合物及其用途
CN114621135B (zh) * 2020-12-11 2024-01-30 上海拓界生物医药科技有限公司 一种lpa1小分子拮抗剂
CN117355507A (zh) 2021-03-23 2024-01-05 哈利亚治疗公司 用作lrrk2激酶抑制剂的嘧啶衍生物
JP2024517769A (ja) * 2021-04-30 2024-04-23 ビバ スター バイオサイエンシズ （スージョウ） カンパニー リミテッド Ｌｐａアンタゴニストとしての新規トリアゾール－ピリジン置換ピロリジニル及びテトラヒドロ－２ｈ－ピラニル酢酸化合物
CN117295717A (zh) 2021-05-11 2023-12-26 吉利德科学公司 Lpa受体拮抗剂及其用途
MX2024001829A (es) * 2021-08-12 2024-04-26 Shanghai Simr Biotechnology Co Ltd Derivado de triazol sustituido, metodo de preparacion del mismo, composicion farmaceutica del mismo y uso del mismo.
CA3238094A1 (fr) 2021-12-08 2023-06-15 Gilead Sciences, Inc. Antagonistes du recepteur lpa et leurs utilisations
TW202342017A (zh) 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物
WO2024138173A1 (fr) * 2022-12-23 2024-06-27 Bristol-Myers Squibb Company Antagonistes de lpa1 pour le traitement d'une maladie pulmonaire interstitielle
WO2024138156A1 (fr) * 2022-12-23 2024-06-27 Bristol-Myers Squibb Company Antagonistes de lpa1 pour le traitement d'une pneumopathie interstitielle
US20240252476A1 (en) * 2022-12-23 2024-08-01 Bristol-Myers Squibb Company Lpa1 antagonists for treating interstitial lung disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4396808B2 (ja) 2001-02-08 2010-01-13 小野薬品工業株式会社 Ｌｐａ受容体調節剤からなる泌尿器疾患治療剤
DE102004038403B4 (de) 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
EP2462128B1 (fr) 2009-08-04 2016-09-21 Amira Pharmaceuticals, Inc. Composés en tant qu'antagonistes du récepteur de l'acide lysophosphatidique
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
JP2014508111A (ja) 2010-12-07 2014-04-03 アミラ ファーマシューティカルス，インコーポレーテッド リゾフォスファチジン酸受容体アンタゴニスト、その線維症の治療における使用
US8785442B2 (en) 2011-01-30 2014-07-22 Curegenix, Inc. Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
JP5976011B2 (ja) 2011-04-05 2016-08-23 武田薬品工業株式会社 スルホンアミド誘導体およびその用途
WO2012138648A1 (fr) * 2011-04-06 2012-10-11 Irm Llc Compositions et procédés pour la modulation de récepteurs au lpa
WO2013070879A1 (fr) 2011-11-10 2013-05-16 Bristol-Myers Squibb Company Méthodes de traitement de lésion de la moelle épinière par des antagonistes du récepteur du lpa
US20140329871A1 (en) 2011-12-04 2014-11-06 Angion Biomedica Corp. Small molecule anti-fibrotic compounds and uses thereof
CA2869541A1 (fr) * 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag Composes n-alkyltriazole utilises comme antagonistes de lpar
CA2869564A1 (fr) 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag Composes n-aryltriazole utilises comme antagonistes de lpar
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
CN112189010A (zh) 2017-12-19 2021-01-05 百时美施贵宝公司 作为lpa拮抗剂的三唑n-连接的氨基甲酰基环己基酸

Also Published As

Publication number Publication date
ES2936517T3 (es) 2023-03-17
US20210230143A1 (en) 2021-07-29
MX2020005323A (es) 2020-08-13
WO2019126093A1 (fr) 2019-06-27
IL275346A (en) 2020-07-30
CA3085561A1 (fr) 2019-06-27
TW202017918A (zh) 2020-05-16
AU2018392324A1 (en) 2020-08-06
US11267800B2 (en) 2022-03-08
CN112055711A (zh) 2020-12-08
CN112055711B (zh) 2024-07-23
BR112020011965A2 (pt) 2020-11-17
KR20200100719A (ko) 2020-08-26
JP7208240B2 (ja) 2023-01-18
SG11202005698XA (en) 2020-07-29
JP2021506860A (ja) 2021-02-22
EP3728223B1 (fr) 2022-12-28

Similar Documents

Publication Publication Date Title
US11267800B2 (en) Cyclohexyl acid triazole azines as LPA antagonists
AU2018392321B2 (en) Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
EP3728242B1 (fr) Acide cyclohexyle isoxazole azoles en tant qu'antagonistes de lpa
EP3852746B1 (fr) Acides cyclopentyliques utilisés comme antagonistes de lpa
EP3728196B1 (fr) Acides carbamoyle cyclohexyliques à liaison o pyrazole utilisés en tant qu'antagonistes de lpa
EP3728222B1 (fr) Azines pyrazoles d'acide cyclohexyle utilisés en tant qu'antagonistes de lpa
EP3728224B1 (fr) Azoles triazoles d'acide cyclohexyle utilisés en tant qu'antagonistes de lpa
EP3728216B1 (fr) Acides carbamoyle cyclohexyliques à liaison n pyrazole utilisés en tant qu'antagonistes de lpa
EP3728209A1 (fr) Azines isoxazole d'acide de cyclohexyle en tant qu'antagonistes de lpa
EP3727589B1 (fr) Acides pyrazoles azoles cyclohexyliques utilisés en tant qu'antagonistes de lpa
EP3852747B1 (fr) Acides cycloheptyliques utilisés comme antagonistes de lpa
WO2019126099A1 (fr) Acides carbamoyle cyclohexyliques à liaison n isoxazole utilisés en tant qu'antagonistes de lpa
WO2019126084A1 (fr) Acides carbamoyle cyclohexyliques à liaison o isoxazole utilisés en tant qu'antagonistes de lpa
WO2020257135A1 (fr) Acides triazole carboxyliques en tant qu'antagonistes de lpa
WO2020257139A1 (fr) Acides cyclobutyl-carboxyliques utilisés comme antagonistes de lpa

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200713

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210726

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20220302

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20220811

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602018044837

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1540411

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230115

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2936517

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20230317

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221228

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230328

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221228

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221228

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20221228

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1540411

Country of ref document: AT

Kind code of ref document: T

Effective date: 20221228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221228

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221228

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221228

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230329

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230404

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221228

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221228

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230428

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221228

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221228

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221228

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221228

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230428

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221228

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602018044837

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221228

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20230929

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231102

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221228

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20231110

Year of fee payment: 6

Ref country code: FR

Payment date: 20231108

Year of fee payment: 6

Ref country code: DE

Payment date: 20231031

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240116

Year of fee payment: 6

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221228

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20231231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221228

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231218

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231231